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1. Abstract 
Colorectal cancer is the third most common cancer worldwide. The APC mutation is 
the first crucial step initiating tumor development in the colon. The consequence of 
this mutation is the progressive up-regulation of the wnt pathway. Consequently, this 
pathway is a prominent target of therapy. Sulindac is a drug inhibiting wnt-signalling 
that is already used in prevention therapy. In the human colon adenoma cell line LT97 
a CD44+ subpopulation was identified that express high FGF18 and survivin and 
down-regulate the IGF-binding protein 3 (IGFBP3). Whether these events are causally 
related to wnt-signalling activity is not yet known, however. 
 
In my diploma thesis I studied the impact of sulindac treatment on the RNA and 
protein expression levels of survivin, FGF18 and IGFBP3 in LT97 adenoma cells and 
in the colorectal cancer cell line HT29. 
Sulindac caused a down-regulation of the wnt target gene survivin to 28% and 61% of 
the control in HT29 and LT97 cells respectively. The drug did not change IGFBP3 
RNA levels in LT97 cells. In HT29 cells sulindac caused a slight elevation of IGFBP3 
RNA levels. 
 
In order to obtain a specific positive control for wnt blockade a dominant-negative 
Tcf4 mutant was cloned into an adenoviral construct. The resulting virus facilitates the 
transduction of all human cell lines. 
HT29 and LT97 cells were transduced with this adenovirus. Tcf4 was expressed 4.7-
fold and 1.7-fold in LT97 and HT29 cells respectively. No other significant effects on 
survivin, FGF18 and IGFBP3 could be detected. 
The sulindac results showed that survivin but not FGF18 and IGFBP3 is regulated in a 
wnt-dependent manner. Mechanistic experiments with the newly produced Tcf4 virus 
will be necessary to actually demonstrate the wnt dependent reaction. 
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2. Introduction 
2.1 Definition of cancer 
Cancer is defined as a disease of abnormal deregulated cell division and 
subsequent invasion of other tissues. The malignant cells can spread to 
other body parts through the blood and lymph systems. Normally, cells 
grow and divide in a controlled manner. In cancer cells genetic mutations 
accumulate and increasingly prevent cell death when necessary and cause 
cell production without stimulatory signals (see figure 2.1.1). Cancer cells 
and their microenvironment form a tissue termed tumor which can be 
benign or malignant. Benign tumors can be curatively removed and do not 
spread to other body parts. Malignant tumors are cancerous and invade 
other tissues, a process which is called metastasis. Carcinomas are cancers 
that arise in the skin or epithelial tissues which internal organs (National 
Cancer Institute – Cancer definition). 
 
Figure 2.1.1 Loss of normal growth control in cancer cells 
(http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer) 
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2.2 Epidemiology of cancer 
2.2.1 General cancer statistics 
In 2008 12.7 millions new cancer cases and 7.6 millions cancer cases are 
counted worldwide. The numbers are age-standardized rates (ASR) in 
order to compare between countries because age has a strong influence on 
the incidence of cancer.  In the incidence of cancer is extremely high in 
Australia/New Zealand (ASR 356.8 per 100000), closely followed by 
Northern America (ASR 334) and Western and Northern Europe (ASR 
288.9 and 335.3). The high rates are the consequence of elevated 
incidence of prostate cancer in males (ASR higher than 80) and breast 
cancer in women (ASR higher than 75) in the concerning regions. The 
lowest incidence rates are recorded in Northern Africa for women and 
Middle and Western Africa and in South-Central Asia for men. 
Interestingly, the incidence of cancer is much higher in developed regions 
than developing countries but the mortality is similar. These relationships 
are depicted in figures 2.2.1.1, 2.2.1.2 and 2.2.1.3. (Globocan for all 
cancers 2008). 
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Figure 2.2.1.1 Cancer incidences in women and men in different 
world regions: estimated age-standardized rates per 100000 (Globocan for all 
cancers 2008) 
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0      88.8  145.9  303.7      361
 
Figure 2.2.1.2 Cancer incidences in men worldwide in 2008 
Age-standardized incidence rates per 100000 (adapted figure Globocan for all cancers 
2008) 
 
0    100.3  142.6   210.8      326
 
Figure 2.2.1.3 Cancer incidences in women worldwide in 2008 
Age-standardized incidence rates per 100000 (adapted figure Globocan for all cancers 
2008) 
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Worldwide the most frequent cancers in men are lung, prostate, 
colorectum, stomach and liver cancer. In women the list is headed by 
cancers of the breast, colorectum, cervix uteri, lung and stomach cancer 
worldwide. These facts are depicted in figures 2.2.1.4 and 2.2.1.5 
(Globocan Fast Stats world 2008). 
 
Figure 2.2.1.4 The most frequent cancers in men worldwide 
( Globocan Fast Stats world 2008) 
 
Figure 2.2.1.5 The most frequent cancers in women worldwide 
(Globocan Fast Stats world 2008) 
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The risk of developing cancer before age 75 is 21.2% for males and 
16.5% for females worldwide. The risk of dying from cancer before age 
75 is 13.4% for males and 9.1% for females ( Globocan Fast Stats world 
2008). The most frequent cancers in Austria are shown in figure 2.2.1.6 
and 2.2.1.7.  
 
Figure 2.2.1.6 The most frequent cancers in men in Austria 
( Globocan Fast Stats Austria 2008) 
 
 
Figure 2.2.1.7 The most frequent cancers in woman in Austria 
( Globocan Fast Stats Austria 2008) 
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In Austria the most frequent cancers in men are prostate, lung, 
colorectum, bladder and kidney cancer. For women they are breast, 
colorectum, lung, corpus uteri and pancreas cancer. The risk of 
developing cancer before age 75 is 27.8% for males and 19.7% for 
females in Austria. The risk of dying from cancer before age 75 is 13.3% 
for males and 8.6% for females (Globocan Fast Stats Austria 2008). 
2.2.2 Colorectal cancer statistics 
Worldwide colorectal carcinoma is the third most common cancer type in 
men (10%) and the second in women (9.4%). 60% of colorectal cancer 
cases occur in developed regions. The highest rates are observed in 
Australia/New Zealand and Western Europe. The lowest rates are in 
Africa and South and Central Asia. Colorectal cancer occurs more 
frequently in men than in woman. Colorectal cancer causes 8% of overall 
cancer deaths. The highest mortality rates are seen in Central and Eastern 
Europe. Worldwide incidents rates are depicted in figure 2.2.2.1 
(Globocan colorectal cancer 2008). 
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Figure 2.2.2.1Colorectal cancer incidences of colorectal cancer 
worldwide: estimated age-standardized rates per 100000 (Globocan colorectal 
cancer 2008) 
 
In Austria between 4600 and 5000 malignant colorectal tumors are 
diagnosed in the colorectal region each year. This represents 13% of all 
new cases of malignant diseases. 1988 more women than men developed 
colorectal cancer in Austria but from 1994 on the gender ratio has 
reversed. So that currently, the risk of developing colorectal is higher in 
men than women. 4 of 100 men but only 2 of 100 women developed 
colorectal cancer till the age of 75 in the year 2008. The risk of dying 
from colorectal cancer before the age of 75 has been declining over the 
past 20 years (2% to 1.1%) as consequence of early diagnosis of 
adenomas.  
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The incidence and mortality rates for malignant neoplasms of the intestine 
in Austria are shown in figure 2.2.2.2 (Statistik Austria 2011). 
Incidence Mortality
male
female
male
female
  
Figure 2.2.2.2 Incidence and mortality rates for malign neoplasms of 
the intestine in Austria: age-standardized rates per 100000  
(adapted Statistik Austria 2011)   
 
 
 
2.3 Tumor development 
2.3.1 General features of tumor development 
As mentioned above genetic alterations are important factors in the 
pathogenesis of cancer. The relevant mutations can be in oncogenes 
resulting in dominant gain of function as well as in tumor suppressor 
genes causing recessive loss of function (Hanahan and Weinberg 2000).  
The gain of function mutation of proto-oncogenes turns them into 
oncogenes that enhance proliferation and survival of cells (Alberts 2008). 
Important examples are the RAS-oncogenes which is mutated in 50% of 
all colon carcinomas (Kinzler and Vogelstein 1996). Tumor suppressor 
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genes prevent cancer in their wild type version and their recessive loss 
supports cancer e.g. Rb gene (Alberts 2008). 
The mutations can be point mutations as well as more severe changes in 
the chromosomes.  
Thus cancer is a disease of dynamic changes in the genome. In humans 
tumorigenesis is a multistep process (also see figure 2.1.1). These steps 
are genetic alterations which cause the progressive transformation of 
normal human cells into highly malignant cancer cells. Hence the process 
of  tumor development can be compared with the Darwinian evolution in 
which the succession of genetic changes leads to growth advantages and 
they cause the progressive transformation of normal human cells into 
cancer cells (Hanahan and Weinberg 2000). Thus the process is 
characterized by new cell phenotypes and selection of those populations 
that grow best (Schulte-Hermann et al. 1999). 
Hanahan and Weinberg (2000) explained in their review “hallmarks of 
cancer” that cancer cells have six essential acquired capabilities that cause 
malignant growth. These hallmarks include self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis 
(programmed cell death), limitless replicative potential, tissue invasion, 
metastasis and sustained angiogenesis (see figure 2.3.1.1). The sequence 
of the acquisition of these capabilities and thus the pathway how the cells 
become malignant is very variable. Therefore the capabilities can occur at 
different stages of the transformation. One genetic event can cause the 
acquisition of more than one capability or only partially support a single 
capability (see figure 2.3.1.2). 
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Figure 2.3.1.1 The 6 essential acquired capabilities of cancer cells 
(Hanahan and Weinberg 2000) 
 
 
Figure 2.3.1.2 The very variable sequence of acquisition of the 
acquired capabilities 
(Hanahan and Weinberg 2000) 
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Various anti-cancer defense mechanisms such as cell cycle checkpoints 
and DNA repair machinery prohibit these 6 acquired capabilities and thus 
cancer stays a rare event in human life. Therefore mutations in these 
defense mechanisms lead to increased mutability and genome instability. 
Under such conditions multiple mutations which are found in tumor cells 
become more likely. A very important example is the p53 tumor 
suppressor which responses to DNA damage either with cell cycle arrest 
or apoptosis (Hanahan and Weinberg 2000). Normal p53 function is lost 
in most human cancers (Levine 1997). 
 
2.3.2 The initiation-promotion-progression model   
The multistage concept shows that malignant cells develop stepwise in a 
sequence of intermediary cells which distinguish increasingly from the 
original cell. The population of intermediary cells originates from single 
cells (“clonal genesis”) and they grow faster than the original tissue. This 
proliferative advantage is low in early stages and increases during 
cancerogenesis. 
The development of cancer can be divided into 3 different stages: 
Initiation – Promotion – Progression (see figure 2.3.2.1) 
Initiation: Initiation is caused by carcinogens and leads to the first 
mutation. Non-mutational causes of initiation are also possible e.g. 
epigenetic mechanisms. Initiation is a persistent transformation which is 
transmitted to daughter cells and causes a proliferation advantage for 
initiated cells. It is an infrequent event and does not lead to tumor 
formation alone. 
Promotion: It is the process that accelerates tumor cell growth by 
creating a growth advantage for initiated cells leading to selective 
expansion of initiated cells. Promotion without initiation does not have a 
tumorigenic effect. Promotion requires a longer period. Mutations and 
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genotoxic events are not essential for promotion. Promotion is 
characterized by enzyme induction and growth. Tumor promotion is a 
reversible process at least in early stages. Thus the effect of promotion can 
vanish when the treatment with promoters is terminated. 
Progression: Initiation and promotion only cause benign tumors. The 
malignant transformation of these cells is called progression. It is an 
accumulation of new mutations because more than one mutation is 
necessary for malignancy. The malignant cells show increased autonomy 
and the potential for metastasis. Progression is characterized by genome 
instability in which the mutated tumor suppressor gene p53 plays a 
prominent role (Schulte-Hermann 1999). 
 
Figure 2.3.2.1 Initiation-promotion-progression model 
(Modified Schulte-Hermann R. 2004. In Hiddemann W, Huber H, et al. (eds.): Die 
Onkologie. Berlin – Heidelberg, Germany: Springer Verlag)  
 
2.3.3 The causes of cancer 
The transformation into malignant tumor cells is characterized by 
mutations. These changes are caused by interaction between the genome 
of the single person and 3 different categories of external agents: 
• Physical carcinogens: e.g. ionizing radiation, UV-light 
• Chemical carcinogens: e.g. tobacco smoke, alcohol, asbestos 
• Biological carcinogens: e.g. certain viruses such as Hepatitis B and 
C and certain types of Human Papilloma Virus 
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Ageing also increases the probability of cancer if they are carcinomas. 
Risk factors of cancer are tobacco use, alcohol consumption, unhealthy 
nutrition, overweight, physical inactivity, air pollution and infection with 
certain viruses e.g. through sexual transmission (WHO 2011). 
Although a person avoids general cancer risks he or she can develop 
cancer because of genetic predisposition. This means that a person is 
already born with a mutation which can cause cancer. An example for that 
are the breast cancer genes BRCA1 and BRCA1. Women who carry one 
of these mutated genes develop breast cancer with higher likelihood. The 
genetic predisposition is also possible for colorectal cancer (Cancer 
Research UK). However, cancer development is a very complex process. 
A germline mutation which causes predisposition for cancer does not lead 
automatically to cancer. In fact cancer is unlike classic genetic diseases 
such as cystic fibrosis a strong interaction between heredity and 
environmental factors. The reason for that is that additional mutations are 
necessary and environmental factors affect mutation rates. This explains 
why diets of large amounts of red meat lead to higher rates of colorectal 
cancer (Kinzler and Vogelstein 1996). 
2.4 Anatomy of colon  
The large intestine (Intestinum crassum) is 1.5-1.8m long and is located 
after the small intestine (Intestinum tenue). One segment of the large 
intestine is the colon which is located between the caecum and the rectum. 
The colon is divided into Colon ascendends, Colon transversum, Colon 
descendens and Colon sigmoideum. The colon is characterized by Taeniae 
coli which are 1cm broad thickenings of the outer longitudinal muscle 
layer and contraction rugae (Plicae semilunares coli). Characteristic 
protrusions (Haustra coli) emerge between 2 Plicae semilunares coli 
(Taschenatlas 2003). 
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The function of the Intestinum crassum is the resorption of water. 
The intestine is generally composed of several layers of tissue: At the 
luminal side the Tunica mucosa resides. It consists of the Lamina 
epithelialis mucosae (epithelial layer), the Lamina propria mucusae 
(connective tissue including blood and lymphatic vessels, smooth muscle 
cells) and the lamina muscularis mucosae (smooth muscle cells). Next to 
the Tunica mucosa the Tela submucosa is located (blood and lymphatic 
vessels and Plexus submucosus as a part of the enteric nervous system). 
After the Tela submucosa the Tunica musularis is situated which consists 
of an inner circular layer of smooth muscle cells and an outer layer of 
longitudinal layer of smooth muscle cells. The Tunica musularis is 
important for peristalsis of the intestine and includes the Plexus 
myentericus as second part of the enteric nervous system. The last part of 
the intestine is the Tunica serosa which has a smooth surface in order to 
support movement of the intestine (see figure 2.4.1) 
 
 
Figure 2.4.1 The layers of the intestine 
(Junqueira 2002) 
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The Tunica mucosa of the small intestine is characterized by Villi 
intestinalis which are evaginations of the Lamina epithelialis and Lamina 
propria. Between the villi are crypts of Lieberkühn (glands) which sink 
into the Lamina propria (Junqueira 2002).  
In contrast to the small intestine the mucosa of the colon does not have 
villi but a flat surface (Reya and Clevers 2005). The colon also has crypts 
which can be 0.5mm deep (Junqueira 2002). 
 
2.5 Tumor stem cells, Wnt pathway and colorectal cancer 
development 
The epithelium of the small intestine consists of differentiated cells and 
stem/progenitor cells. Spatially, the differentiated cells like enterocytes, 
enteroendocrine cells and goblet cells are located at the villi and the 
Paneth cells (produce antimicrobial agents) and stem/progenitor cells 
reside in the crypts. 
In the colon stem/precursor cells are at the bottom 2/3 of the crypts and 
the differentiated cells cover the top third of the crypts and the surface of 
the lumen. 
The life expectancy of an intestinal epithelial cell is less than a week. 
Thus an enormous amount of cells is generated per day at the bottom of a 
crypt and lost on the top. Only stem cells and Paneth cells can escape this 
continuous flow of cells.  
Colon stem cells are located at the crypt bottom and they produce transit 
amplifying cells which rapidly proliferate and are able to differentiate in 
all concerning cell types populating the crypt. The tasks of the colon stem 
cells are self-renewal and differentiation but also regeneration of the 
epithelium after injury. Eventually, the committed progenitors enter cell 
cycle arrest and express differentiation markers when they arrive the top 
third of the crypts (see figure 2.5.1). 
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Figure 2.5.1 Colon stem cells 
(Reya and Clevers 2005) 
 
The canonical Wnt pathway is the dominant force in cell fate and drives 
the genetic programme in stem/progenitor cells of the crypts. 
The central player of the Wnt pathway is β-catenin whose stability is 
regulated by a destruction complex. β-catenin also resides in cadherin 
cell-cell adhesions. Signalling is initiated when a Wnt ligand binds to a 
receptor complex which consists of Frizzled (serpentine receptor) and 
Lrp5/6 (LDL receptor family). In the absence of ligand the two 
scaffolding proteins complex APC ( adenomatous polyposis coli) and axin 
bind to β-catenin. In this case GSK3 kinase phosphorylates the amino 
terminus of β-catenin. This phosphorylation leads to ubiquitination and 
subsequent proteasomal degradation. If a Wnt ligand binds the receptors 
GSK3 is inhibited and thus β-catenin accumulates and enters the nucleus 
where it binds the N-terminus of Tcf/Lef (DNA-binding protein). If β-
catenin is absent Tcf/Lef is associated with co-repressors like Groucho 
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and this leads to repression of target genes. Tcf/Lef is converted into a 
transcriptional activator by binding to β-catenin (see figure 2.5.2). 
 
Figure 2.5.2 Wnt pathway 
(Reya and Clevers 2005) 
This is the important function of the Wnt pathway in colorectal 
stem/progenitor cells. Interestingly, the activation of the Wnt pathway 
also plays a crucial role in colorectal cancer.  
APC was discovered as the underlying germ line mutation in familial 
adenomatous polyposis (FAP) which is an autosomal, dominantly 
inherited cancer syndrome affecting 1 in 7000 individuals. Those FAP 
patients who have one defective APC allele (chromosome 5q21 locus) 
frequently also lose the other allele by mutation or deletion and then 
develop a lot of adenomas (polyps) in their early life. If you examine a 
single adenoma they are clonal outgrowths of epithelial cells whose 
second APC allele is mutated or deleted (Kinzler and Vogelstein 1996; 
Reya and Clevers 2005). 
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The germline mutation of APC does not automatically lead to colorectal 
cancer but FAP patients have a higher risk to develop colorectal cancer. 
The rate-limiting step seems to be the somatic mutation of the wildtype 
APC allele (Kinzler and Vogelstein 1996). 
Over time additional mutations of oncogenes or tumor suppressor genes 
accumulate in FAP patients and only those lead to colorectal carcinoma 
development.  
APC is also lost in most sporadic colorectal cancers and consequently, 
tumor development is initiated with a mutational activation of the Wnt 
pathway. The inactivation of APC causes the aberrant stabilization of β-
catenin and subsequently, the inappropriate activation of the Wnt pathway 
transforms the epithelial cells. DNA microarray analysis has shown that 
the same genetic programmes are activated through the Wnt pathway 
activation in colorectal cancer that are active in physiological 
stem/progenitor cells. When adenoma cells activate the Wnt pathway they 
maintain their progenitor status for an unlimited time. This feature allows 
them to exist for many years and enables the cells to acquire further 
mutations (Reya and Clevers 2005). 
 
Thus, in most cases the initiating event of the intestinal neoplastic process 
is an APC mutation with the effects mentioned above. Subsequently, 
patients develop dysplastic aberrant crypt foci (ACF) and early adenoma. 
Other mutations occur during progression. 50% of colorectal carcinoma 
and an equal number of adenomas greater than 1 cm have K-RAS 
mutation but this mutation alone cannot lead to initiation of tumor 
development. Just one genetic event is necessary for activation of K-RAS. 
It occurs in a small adenoma and leads to a larger and stronger dysplastic 
tumor (intermediate adenoma) through clonal expansion. 70% of 
carcinomas lose several different tumor suppressors on 
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chromosome18q21 (e.g.DCC). Finally, a loss of a large portion of 
chromosome 17p is detected in more than 75% of colorectal carcinomas 
but this can be detected infrequently in adenomas. This region includes 
p53 which is an important tumor suppressor gene. Furthermore p53 
mutations occur in the remaining allels of several colorectal cancers. 
Again the p53 mutation alone cannot initiate the neoplastic process. 
Interestingly, p53 mutation has a dominant negative effect and it leads to a 
selective growth advantage even if a wild-type p53 allele is still working. 
Loss of the wild-type p53 allele leads to the transition of adenomas to 
carcinomas. While the sequence of accumulation of mutations is not 
obligatory, they still occur in a preferred order that is characteristic for 
colorectal cancer. Thus APC seems the gatekeeper in colorectal cancer 
development (Fearon and Vogelstein 1990; Kinzler and Vogelstein 1996). 
See the sequential events of mutations in figure 2.5.3 and the different 
colorectal cancer stages in figures 2.5.4-2.5.5. 
 
 
Figure 2.5.3 Sequential mutation events in colorectal cancer 
development 
(Kinzler and Vogelstein 1996) 
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Adenoma
 
Figure 2.5.4 Adenomas surrounded by normal tissue 
(adapted Wikipedia 2009) 
 
 
 
 
 
Figure 2.5.5 Colorectal carcinoma tissue 
(Camarero et al. 2006) 
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2.6 Introduction of the diploma thesis topic 
As mentioned above colon tumorigenesis is initiated by a mutation of the 
APC tumour suppressor gene which leads to prolonged and stronger 
activation of the WNT-pathway (Fearon and Vogelstein 1990). This 
causes a subsequent accumulation of CD44+ cells with higher survival 
potential in premalignant colorectal adenomas (Schulenburg et al. 2007). 
As mentioned above adenomas are benign neoplasms of epithelial tissue 
which arise from colonic crypts with mutated APC (Fearon and 
Vogelstein 1990). Thus the CD44+ subpopulation of the colorectal 
adenomas can progress to malignant colon carcinoma cells through 
subsequent mutations. CD44 is a WNT target gene and therefore it 
indicates an active WNT pathway (Schulenburg et al. 2007). 
An activated WNT pathway was the main characteristic of a CD44+ 
subpopulation of the LT97 colon adenoma cells that displayed an 
extended survival potential (Schulenburg et al. 2007). In this context 
several survival-related genes have been found differentially regulated in 
CD44+ LT97 cells previous experiments. Among them were survivin, 
FGF18 und IGFBP3 (Schulenburg et al. 2011 manuscript). 
Survivin (BIRC5) is an inhibitor of apoptosis that inactivates caspase 
activity and is a direct WNT target gene (Altieri 2008). FGF18 is also a 
known WNT target gene (Sonvilla et al. 2008) and a ligand of FGFR3-IIIc 
and FGFR4 (Zhang et al. 2006). It is important for cell proliferation, 
survival and migration of colonic tumor cells (Sonvilla et al. 2008). IGF 
binding protein 3 (IGFBP3) is a negative regulator of IGF1 signalling 
which stimulates growth and enhanced cell survival in HT29 and LT97 
(Pollak 2008). Mediated via Akt (PKB) which phosphorylates and 
inactivates GSK3beta IGF-signaling can modulate wnt-pathway activity 
(Guessous et al. 2008). 
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It was observed that IGFBP3 was strongly down regulated in the CD44+ 
subpopulation of LT97 cells so that it is almost exclusively expressed in 
the CD44- subpopulation (Schulenburg et al. 2011 manuscript). It is 
assumed that the active WNT pathway negatively regulates IGFBP3 
expression. In order to underpin this hypothesis sulindac is applied at 
HT29 and LT97 cells in this diploma thesis. Sulindac is a non-steriodal 
anti-inflammatory drug of the arylalkanoic acid class which has many 
effects including the inhibition of the WNT pathway and is used for 
chemoprevention of hereditary colon cancer (Koornstra et al. 2005). 
Although sulindac can down regulate the WNT pathway it is not specific 
enough to prove the hypothesis because it can have side effects which 
cause IGFBP3 up-regulation. Thus a more selective tool to shut down the 
WNT pathway was needed. 
2.7 Aims of the diploma thesis 
The hypothesis of the diploma thesis is that the active WNT pathway 
impacts negatively on the expression of IGFBP3. Thus the inactive WNT 
pathway shall increase IGFBP3 RNA and protein levels.  
The aims of the diploma thesis are: 
1. Sulindac treatment to inhibit wnt target genses such as surviving 
and FGF18 and to prove that this has also impacts on IGFBP3 RNA 
and protein levels in HT29 and LT97 cells. 
2. Production of an adenovirus expressing a truncated ΔN-TCF4 gene 
to interrupt the β-catenin TCF/LEF interaction. 
3.  Specific inactivation of the wnt signalling using the pAd/CMV/V5-
DEST-ΔN-TCF4 virus and investigation of the effects as above. 
 
 
 
26 
27 
 
3. Results 
3.1 Sulindac experiments 
3.1.1 Results on the RNA level 
HT29 and LT97 cells were cultivated and treated with sulindac according 
to 5.1 and 5.2 of the Materials and methods section. The RNA was 
extracted and analyzed according to 5.3 - 5.6 of the Material and 
methods section. Sybr® green I Real Time PCR was used to quantify 
survivin and IGFBP3 in the HT29 and LT97 samples. Taqman® probe 
kits were used to detect FGF18 and IGFBP3 in both cell lines. 
 
The results are shown in figures 3.1.1.1 and 3.1.1.2 as percent values 
relative to the GAPDH house keeping gene and the untreated control 
group. Survivin was down-regulated to 28 ± 18.62% (p = 0.0286) in 
sulindac treated HT29 cells. In LT97 cells the impact was less pronounced 
but survivin was also clearly down-regulated to 61 ±3.55% (p = 0.0286) 
(see figure 3.1.1.1). 
IGFBP3 shows a different picture. On the one hand IGFBP3 might be up-
regulated in HT29 cells (134 % of the control level) but the standard 
deviation was too high providing a significant result. On the other hand it 
was almost unaffected in LT97. 
Sulindac treatment had no effect on FGF18 in HT29 (107% of the control 
level). LT97 cells showed a down-regulation of FGF18 (65% of the 
control level) but the standard deviation was too high for a statistically 
significant result. 
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Figure 3.1.1.1: % in comparison with the control in sulindac treated 
HT29 and LT97 samples (Survivin, FGF18) 
The value of 100 indicates the same value as the control. 
* indicates statistically significant data 
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Figure 3.1.1.2: % in comparison with the control in sulindac treated 
HT29 and LT97 samples (IGFBP3) 
The value of 100 indicates the same value as the control. 
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3.1.2 Results on the protein level 
HT29 cells and LT97 were cultivated and treated with 10µM sulindac 
according to 5.1 and 5.2 of the Materials and methods section. The 
protein was extracted and analyzed by SDS PAGE and Western Blot 
according to 5.7 - 5.10 of the Material and methods section. Survivin 
was detected in both cell lines under sulindac and control conditions. β-
Actin was used for standardization. The bands were analyzed with 
ImageQuant5.0. The results are in figure 3.1.2.1 and in figure3.1.2.2. 
β-Actin
Survivin
HT29 Sulindac HT29 Control
 
Figure 3.1.2.1 HT29 Survivin protein levels 
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β-Actin
Survivin
LT97 SulindacLT97 Control
 
Figure 3.1.2.2 LT97 Survivin protein levels 
 
According to figure 3.1.2.1 and figure 3.1.2.2 sulindac treatment 
decreased Survivin protein levels in HT29 and LT97 cells. These results 
were as expected because Survivin is a WNT target gene and Sulindac 
inhibits this signal pathway. 
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3.2 Transfection of HT29 cells with pbabe-puro-GFP 
It was planned to transfect the pAAV-IRES-hrGFP-ΔN-Tcf4 plasmid  
(Holnthoner et al. 2002) in HT29 cells by lipofection in order to avoid 
cloning into an adenoviral vector and subsequent transduction. This 
possibility was tested with a pbabe-puro-GFP construct. For this purpose 
HT29 cells were transfected with 2µg and 4µg pbabe-puro-GFP plasmid 
in 6-well plates according to 5.13 in the materials and methods section. 
Control cells were not transfected. 24 hours after transfection the cells 
were prepared according to 5.14 in the materials and methods section and 
the GFP expression were evaluated by FACS analysis. The results are 
depicted in figure 3.3.1 and in table 3.3.1. Only a small fraction of cells 
could be transfected but at least 50% of cells shall express the pAAV-
IRES-hrGFP-ΔN-Tcf4 in order to do experiments. 
 
Figure 3.2.1: percentage of GFP expressing HT29 cells 
 
Table 3.2.1: percentage of GFP expressing HT29 cells 
days 2µg plasmid 4µg plasmid 
1 5.31 12.14 
2 7.03 15.87 
3 8.46 11.82 
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3.3 Production of adenoviral Tcf4-vector 
The transfection of  the pAAV-IRES-hrGFP-ΔN-Tcf4 or -VP16- ΔN-Tcf4 
or -Tcf4wt plasmids (see figure 3.3.1) (Holnthoner et al. 2002) were not 
possible according to the results in 3.2 and hence the ΔN-Tcf4 or -VP16- 
ΔN-Tcf4 or -Tcf4wildtype fragments were cloned into an adenoviral 
vector. For this purpose the fragments were cut out of the pAAV-IRES-
hrGFP backbone and cloned into a pENTR vector which delivers the 
insert into the final adenoviral expression vector by gateway cloning. 
 
Figure 3.3.1 pAAV-IRES-hrGFP: ΔN-Tcf4, VP16- ΔN-Tcf4 and 
Tcf4wildtype are inserted into the MCS 
 
3.3.1 Preparation for re-cloning 
First of all the pAAV-IRES-hrGFP-ΔN-Tcf4 or -VP16- ΔN-Tcf4 or -
Tcf4wildtype plasmids were transformed and amplified according to 5.12 
in the material and methods section. The lengths of the inserts are in table 
3.3.1.1. 
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Table 3.3.1.1 insert lengths 
Insert app. length 
ΔN-Tcf4 1700bp 
VP16- ΔN-Tcf4 1950bp 
Tcf4 wildtype 1800bp 
 
See miniprep results for pAAV-IRES-hrGFP-ΔN-Tcf4 in table 3.3.1.2. 
Table 3.3.1.2 pAAV-IRES-hrGFP-ΔN-Tcf4 samples 1 and 2 
Sample Concentration (ng/µl) 
Sample 1 251.14 
Sample 2 170.27 
 
The pAAV-IRES-hrGFP-ΔN-Tcf4 plasmid was analyzed with the 
restriction enzymes EcoRI and XhoI (Fermentas) and 10x buffer H 
(Roche). 
See the results for the digest of pAAV-IRES-hrGFP-ΔN-Tcf4 sample 1 
and 2 at figure 3.3.1.1. The digest of both samples had bands at1700bp 
and therefore they included ΔN-Tcf4. 
5148
2027
1584
sample1    sample2λM
 
Figure 3.3.1.1 pAAV-IRES-hrGFP- ΔN-Tcf4 sample 1 and 2 digest 
with EcoRI and XhoI 
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Sample 1 were amplified and isolated with Midiprep (see results in table 
3.3.1.3). 
Table 3.3.1.3 pAAV-IRES-hrGFP-ΔN-Tcf4 samples 1 and 2 
Sample Concentration (ng/µl) 
Aliquot 1 200 
Aliquot 2 74 
 
The pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 and -Tcf4wt plasmids were 
isolated by miniprep (see results in table 3.3.1.4) and analyzed with the 
restriction enzymes EcoRI and XhoI (Fermentas). See the resulting 
products in figure 3.3.1.2 and table 3.3.1.5. Midiprep aliquot 1 of pAAV-
IRES-hrGFP-ΔN-Tcf4 were also tested and verified. 
The pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 samples showed bands at 250bp 
if they were digested with EcoRI because VP16 is flanked by these 
restriction sites. Thus the double digest of these samples also had bands at 
1700bp because of the remaining ΔN-Tcf4. The double digest of pAAV-
IRES-hrGFP-Tcf4wt samples had bands at 1800bp. 
The pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 sample 2 and pAAV-IRES-
hrGFP-Tcf4wt sample 2 showed that clearly and midiprep was done with 
them (see midiprep results in table 3.3.1.6) 
Table 3.3.1.4 pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 and -Tcf4wt 
Sample Concentration (ng/µl) 
VP16 S1 275.58 
VP16 S2 248.33 
Tcf4 wt S1 251.33 
Tcf4 wt S2 82.25 
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S1  S2  S3 S4 S5  S6  S7 S8          MR λM S9 S10 S11 S12S13S14S15S16S17S18 S19S20 MR
6000
2000
5100
1900
564
1500
Figure 3.3.1.2 EcoRI and XhoI restriction digest 
 
Table 3.3.1.5 sample description of figure 3.3.1.2 
Sample number Sample details 
S1 Tcf4wt sample1 EcoRI and XhoI 
S2 Tcf4wt sample1 EcoRI 
S3 Tcf4wt sample1 XhoI 
S4 Tcf4wt sample1 no restriction enzymes 
S5 VP16-Δ-Tcf4 sample1 EcoRI and XhoI 
S6 VP16-Δ-Tcf4 sample1 EcoRI 
S7 VP16-Δ-Tcf4 sample1 XhoI 
S8 VP16-Δ-Tcf4 sample1 no restriction enzymes 
S9 VP16-Δ-Tcf4 sample2 Eco RI and XhoI 
S10 VP16-Δ-Tcf4 sample2 EcoRI 
S11 VP16-Δ-Tcf4 sample2 XhoI 
S12 VP16-Δ-Tcf4 sample2 no restriction enzymes 
S13 Tcf4wt sample2 EcoRI and XhoI 
S14 Tcf4wt sample2 EcoRI 
S15 Tcf4wt sample2 XhoI 
S16 Tcf4wt sample2 no restriction enzymes 
S17 Δ-Tcf4 aliquot1 EcoRI and XhoI 
S18 Δ-Tcf4 aliquot1 EcoRI 
S19 Δ-Tcf4 aliquot1 XhoI 
S20 Δ-Tcf4 aliquot1 no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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Table 3.3.1.6 midiprep of pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 S2 
and-Tcf4wt S2 
Sample Concentration (ng/µl) 
pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 S2 aliquot 1 136 
pAAV-IRES-hrGFP-Tcf4wt S2 aliquot 1 211 
 
Midiprep of pAAV-IRES-hrGFP-VP16-ΔN-Tcf4 sample 2 and –Tcf4wt 
sample 2 were tested with restriction digests of EcoRI and XhoI 
(Fermentas). Furthermore midiprep samples of pAAV-IRES-hrGFP-ΔN-
Tcf4,-VP16-ΔN-Tcf4 and -Tcf4wt were analyzed with single restriction 
enzyme digests of NotI, BglII (10xFast Digest® Buffer, Fermentas) and 
BamHI (10x buffer B). See the resulting gel photos in figure 3.3.1.3, 
figure 3.3.1.4 and table 3.3.1.7. The expected fragment lengths are in table 
3.3.1.8. 
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S1   S2    S3     S4   λM MR   S5   S6   S7   S8
5000
1900
564
250
Figure 3.3.1.3 EcoRI, XhoI and NotI restriction digests 
S9 S10   S11   λM S12 S13  S14  S15 S16 S17 S18  MR
5000
3000
2027
1375
Figure 3.3.1.4 NotI, BamHI and BglII restriction digest 
39 
 
Table 3.3.1.7 Sample description of figure 3.3.1.3 and 3.3.1.4 
Sample number Sample details 
S1 Midiprep sample Tcf4wt EcoRI and XhoI 
S2 Midiprep sample Tcf4wt EcoRI 
S3 Midiprep sample Tcf4wt XhoI 
S4 Midiprep sample Tcf4wt no restriction enzymes 
S5 Midiprep sample VP16-ΔN-Tcf4 EcoRI and XhoI 
S6 Midiprep sample VP16-ΔN-Tcf4 EcoRI 
S7 Midiprep sample VP16-ΔN-Tcf4 XhoI 
S8 Midiprep sample VP16-ΔN-Tcf4 no restriction enzymes 
S9 Midiprep sample ΔN-Tcf4 NotI 
S10 Midiprep sample Tcf4wt NotI 
S11 Midiprep sample VP16-ΔN-Tcf4 NotI 
S12 Midiprep sample ΔN-Tcf4 BamHI 
S13 Midiprep sample Tcf4wt BamHI 
S14 Midiprep sample VP16-ΔN-Tcf4 BamHI 
S15 Midiprep sample ΔN-Tcf4 BglII 
S16 Midiprep sample Tcf4wt BglII 
S17 Midiprep sample VP16-ΔN-Tcf4 BglII 
S18 Midiprep sample ΔN-Tcf4 no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
Table 3.3.1.8 Expected cutting lengths 
Restriction enzymes Fragments (bp) 
NotI (3 fragments) 1230; 3538 
Tcf4wt: 3824 
ΔN-Tcf4: 3724 
VP16-ΔN-Tcf4: 3974 
BamHI (1 fragment) 
BglII (1 fragment) 
Tcf4wt: 7900 
ΔN-Tcf4: 7800 
VP16-ΔN-Tcf4: 8050 
 
The aim was to excise the Tcf4wt, ΔN-Tcf4 and VP16-ΔN-Tcf4 inserts 
with BamHI and XhoI from the of pAAV-IRES-hrGFP vector. 
Furthermore another attempt was to cut the Tcf4wt, ΔN-Tcf4 and VP16-
ΔN-Tcf4 inserts together with 3x Flag + hrGFP with BamHI and BglII out 
of the rest vector. 
Subsequently, 5µg midiprep samples of pAAV-IRES-hrGFP-Tcf4wt, -
ΔN-Tcf4 and -VP16-ΔN-Tcf4 were digested with BamHI and XhoI or 
BamHI and BglII (see 5.15.1). Aliquots of these large digests were tested. 
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Additionally, single cuts and no cuts were analyzed. See the resulting gel 
photos in figure 3.3.1.5, figure 3.3.1.6 and table 3.3.1.9. The expected 
fragment lengths for the double digest are in table 3.3.1.10. The insert 
Tcf4t, ΔN-Tcf4 and VP16-ΔN-Tcf4 was cut out successfully in samples 
1-3. 
The attempt to cut out Tcf4wt, ΔN-Tcf4 and VP16-ΔN-Tcf4 together with 
3x Flag + hrGFP with BamHI and BglII failed because the products were 
1000bp shorter than predicted from the sequence (see table 3.3.1.10). 
It was likely that at least parts of hrGFP were absent in the pAAV 
plasmids because it was expected that BamHI and BglII excised 
approximately 1000bp bigger fragments. 
Thus the samples 1-3 were used for the further procedures. 
S1    S2    S3   S4    S5    S6   λM MR     S7   S8   S9
1904
4000
5000
6000
2500
3000
8000
 
Figure 3.3.1.5 restriction digests of pAAV-IRES-hrGFP-Tcf4wt, -ΔN-
Tcf4 and -VP16-ΔN-Tcf4 
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S10  S11  S12    λM MR  S13 S14  S15 S16  S17 S18
8000
6000
 
Figure 3.3.1.6 restriction digests of pAAV-IRES-hrGFP-Tcf4wt, -ΔN-
Tcf4 and -VP16-ΔN-Tcf4 
 
Table 3.3.1.9 Sample description of figure 3.3.1.5 and 3.3.1.6 
Sample number Sample details 
S1 Midiprep sample Tcf4wt BamHI and XhoI, 10x buffer B 
S2 Midiprep sample ΔN-Tcf4 BamHI and XhoI, 10x buffer B 
S3 Midiprep sample VP16-ΔN-Tcf4 BamHI and XhoI, 10x buffer B 
S4 Midiprep sample Tcf4wt BamHI and BglII, fast digest 
S5 Midiprep sample ΔN-Tcf4 BamHI and BglII, fast digest 
S6 Midiprep sample VP16-ΔN-Tcf4 BamHI and BglII, fast digest 
S7 Midiprep sample Tcf4wt BamHI, fast digest 
S8 Midiprep sample ΔN-Tcf4 BamHI, fast digest 
S9 Midiprep sample VP16-ΔN-Tcf4 BamHI, fast digest 
S10 Midiprep sample Tcf4wt XhoI, 10x buffer B 
S11 Midiprep sample ΔN-Tcf4 XhoI, 10x buffer B 
S12 Midiprep sample VP16-ΔN-Tcf4 XhoI, 10x buffer B 
S13 Midiprep sample Tcf4wt BglII, fast digest 
S14 Midiprep sample ΔN-Tcf4 BglII, fast digest 
S15 Midiprep sample VP16-ΔN-Tcf4 BglII, fast digest 
S16 Midiprep sample Tcf4wt no restriction enzymes 
S17 Midiprep sample ΔN-Tcf4 no restriction enzymes 
S18 Midiprep sample VP16-ΔN-Tcf4 no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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Table 3.3.1.10 expected cutting lengths for double digest 
Restriction enzymes Predicted fragments (bp) 
BamHI + XhoI  
(2 fragements in each 
sample) 
6100; 
Tcf4wt: 1800 
ΔN-Tcf4: 1700 
VP16-ΔN-Tcf4: 1950 
BamHI + BglII 
(2 fragments in each 
sample) 
4612; 
Tcf4wt: 3288 
ΔN-Tcf4: 3188 
VP16-ΔN-Tcf4: 3438 
 
3.3.2 pENTR vector cloning 
3.3.2.1 pENTR/D-TOPO® vector cloning 
Subsequently, it was tried to clone Tcf4wildtype, ΔN-Tcf4 and VP16-ΔN-
Tcf4 into the pENTR/D-TOPO® because this pENTR clone procedure 
was common in the Holzmann lab. The pENTR/D-TOPO® vector is 
depicted in figure 3.3.2.1.1. 
 
Figure 3.3.2.1.1 pENTR/D-TOPO® vector 
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For this purpose samples 1-3 of the digest in table 3.3.1.9 were treated 
with phosphatase according to 5.15.2. The samples contained 4µg DNA 
which was approximately 3 picomoles DNA ends. Thus 0.03u CIAP was 
necessary and 5µl of the phosphatase treatment master mix was taken. 
After that the success of the phosphatase treatment was tested with a re-
ligation check according to 5.15.3. 5µl of the phosphatase treated samples 
were transformed into 160µl competent TOP10 cells together with a 
pUC19 control. The results of the re-ligation check are in table 3.3.2.1.1. 
Only the phosphatase treatment of sample 1 (pAAV-IRES-hrGFP-Tcf4wt) 
was successful because the colony numbers of the control were 10 times 
higher than the phosphatase treated sample. Sample 2 and 3 had 
approximately equal colony numbers. The used DNA amounts are listed 
in table 3.3.2.1.2. The ratio of the DNA amount of the controls and the 
phosphatase treated samples was approximately 100:80 in the re-ligation 
check. Thus this could not interfere significantly with the comparison of 
the colony number of controls and phosphatase treated samples. The 
phosphatase seems to work inefficiently. pAAV-IRES-hrGFP-Tcf4wt 
restriction digest (figure 3.3.1.5) was incomplete and there was a big band 
at approximate 7000bp which showed that only 1 restriction enzyme cut 
there (see figure 3.3.1.5). Subsequently, pAAV-IRES-hrGFP-Tcf4wt 
restriction digest (figure 3.3.1.5) had fewer ends than the other samples 
and thus phosphatase could work better there. On the other hand figure 
3.3.1.5 shows that more DNA was digested of pAAV-IRES-hrGFP-
Tcf4wt. 
Table 3.3.2.1.1 Results of the re-ligation check 
Sample Colonies 1:50  Colonies of 
undiluted rest 
Phosphatase treatment of sample 1 5 200 
Untreated sample 1 control 57 1000 
Phosphatase treatment of sample 2 7 200-300 
Untreated sample 2 control 9 approx. 50 
Phosphatase treatment of sample 3 15 approx. 100 
Untreated sample 3 control 14 approx. 100 
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Table 3.3.2.1.2 DNA amounts 
Procedures Control Treated samples 
Restriction digest 5µg 5µg 
Phosphatase treatment  4µg (80ng/µl) 
Ligation 0.1µg (10ng/µl) 80ng (8ng/µl) 
Transformation 50ng 40ng 
 
The phosphatase treated constructs were converted into blunt ends 
according to 5.15.4. 
Sample 1 (Tcf4wt) which was treated with phosphatase and converted 
into blunt ends was cloned into the pENTR/D-TOPO® (kanamycin 
resistance) according to 5.15.5. Subsequently, the resulting vector was 
transformed into 200µl competent TOP10 bacteria together with a pUC19 
control plasmid (ampicillin resistance) and a pENTR/D-TOPO®-IIIC 
control plasmid. The resulting colony numbers are listed in table 3.3.2.1.3. 
The transformation rates are in table 3.3.2.1.4. pUC19 control gave much 
more colonies than pENTR/D-TOPO®-IIIC control. The transformation 
rate of pENTR/D-TOPO®-IIIC control was lower. pENTR/D-TOPO® 
constructs had a decreased transformation efficiency, especially if 
transformation was used for selection as in the case of the produced 
pENTR/D-TOPO®-Tcf4wt plasmid. The 2 colonies of pENTR/D-
TOPO®-Tcf4wt undiluted plate were picked and transferred in 14ml 
tubes which are filled with 7ml liquid LB and kanamycin and then they 
were shaken at 200 rpm at 37°C overnight. DNA was isolated by miniprep 
(see results in table 3.3.2.1.5), digested with EcoRI and EcoRV (2µl 
miniprep samples) and analyzed by 1% agarose gel electrophoresis (see 
figure 3.3.2.1.2 and table 3.3.2.1.6). 
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Table 3.3.2.1.3 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control 65 Lawn 
pENTR-IIIC control 2 28 
pENTR-Tcf4wt 0 2 
 
Table 3.3.2.1.4 Transformation rates 
Plate Colony numbers at 1µg 
pUC19 1:50 dilution (20pg) 3250000 
pENTR-IIIC 1:50 dilution (20pg) 100000 
pENTR-IIIC rest (1ng) 28000 
 
Table 3.3.2.1.5 Miniprep results of possible pENTR-Tcf4wt 
Sample Concentration (ng/µl) 
pENTR-Tcf4wt Colony1 92.84 
pENTR-Tcf4wt Colony2 88.34 
 
The pENTR/D-TOPO®-IIIC control transformation results (see table 
3.3.2.1.4) indicated a decreased transformation efficiency in addition to 
the lower chance that correct pENTR/D-TOPO®-Tcf4wt plamids could 
be ligated. 
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λM E1  E2    E3    E4    E5    E6     E7    E8  MR  
1500
2000
2500
3000
2027
Figure 3.3.2.1.2 Digest of first production attempt of pENTR/D-
TOPO-TCF4wt 
 
Table 3.3.2.1.6 Sample description of figure 3.3.2.1.2 
Sample number Sample details 
E1 pENTR/D-TOPO®-Tcf4wt colony1 EcoRI, EcoRV, buffer B 
E2 pENTR/D-TOPO®-Tcf4wt colony2 EcoRI, EcoRV, buffer B 
E3 pENTR/D-TOPO®-Tcf4wt colony1 EcoRI, buffer B 
E4 pENTR/D-TOPO®-Tcf4wt colony2 EcoRI, buffer B 
E5 pENTR/D-TOPO®-Tcf4wt colony1 EcoRV, buffer B 
E6 pENTR/D-TOPO®-Tcf4wt colony2 EcoRV, buffer B 
E7 pENTR/D-TOPO®-Tcf4wt colony1 no restriction enzymes 
E8 pENTR/D-TOPO®-Tcf4wt colony2 no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
EcoRI only cut once in the insert and EcoRV cut once in the pENTR/D-
TOPO® vector and in the correct pENTR/D-TOPO®-Tcf4wt sample. The 
expected fragments for the empty pENTR/D-TOPO® vector and 
pENTR/D-TOPO® +insert are listed in table 3.3.2.1.7. 
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Table 3.3.2.1.7 Expected fragments for EcoRI and EcoRV digests 
Restriction enzymes Fragments (bp) 
EcoRV (cut once in 
vector) or EcoRI 
Empty vector: 2576 (EcoRI does not cut) 
Vector + Tcf4wt: 4387 
Vector + ΔN-Tcf4: 4297 
Vector + VP16-ΔN-Tcf4: 4546 
EcoRV and 
EcoRI (cuts in insert) 
Empty vector: 2576 
Vector + Tcf4wt sense: 1939; 2448 
Vector+ Tcf4wt antisense: 133; 4254 
Vector + ΔN-Tcf4 sense: 1849; 2448 
Vector + ΔN-Tcf4 antisense: 133; 4164 
Vector + VP16-ΔN-Tcf4 sense: 249; 1849; 2448 
Vector + VP16-ΔN-Tcf4 antisense: 249; 133; 4164 
 
Figure 3.3.2.1.2 showed that pENTR/D-TOPO® vector did not ligate with 
Tcf4wt. Thus the procedure had to be changed in order to gain pENTR/D-
TOPO®-Tcf4wt, -ΔN-Tcf4 and -VP16-ΔN-Tcf4. It was decided to elute 
the digested fragments from the gel in order to gain purified products 
which have higher phosphatase treatment efficiency. 
The large digest was repeated: 5µg midiprep samples of pAAV-IRES-
hrGFP-Tcf4wt, -ΔN-Tcf4 and -VP16-ΔN-Tcf4 were digested with BamHI 
and XhoI (see 5.15.1). Aliquots of these large digests were tested. 
Additionally, single cuts and no cuts were analyzed. See the resulting gel 
photos in figure 3.3.2.1.3 and table 3.3.2.1.8. The expected fragment 
lengths for the double digest are in table 3.3.1.10. 
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Figure 3.3.2.1.3 restriction digests of pAAV-IRES-hrGFP-Tcf4wt, -
ΔN-Tcf4 and -VP16-ΔN-Tcf4 
 
Table 3.3.2.1.8 Sample description of figure 3.3.2.1.3 
Sample number Sample details 
N1 Midiprep sample Tcf4wt BamHI and XhoI, buffer B 
N2 Midiprep sample ΔN-Tcf4 BamHI and XhoI, buffer B 
N3 Midiprep sample VP16-ΔN-Tcf4 BamHI and XhoI, buffer B 
N4 Midiprep sample Tcf4wt BamHI, buffer B 
N5 Midiprep sample ΔN-Tcf4 BamHI, buffer B 
N6 Midiprep sample VP16-ΔN-Tcf4 BamHI, buffer B 
N7 Midiprep sample Tcf4wt XhoI, buffer B 
N8 Midiprep sample ΔN-Tcf4 XhoI, buffer B 
N9 Midiprep sample VP16-ΔN-Tcf4  XhoI, buffer B 
N10 Midiprep sample Tcf4wt no restriction enzymes 
N11 Midiprep sample ΔN-Tcf4 no restriction enzymes 
N12 Midiprep sample VP16-ΔN-Tcf4 no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
The repetition of the large digest of pAAV-IRES-hrGFP-ΔN-Tcf4 failed 
and was repeated successfully again (see figure 3.3.2.1.4 and table 
3.3.2.1.9). The volume of this large digest was smaller than the other 
digests.  
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Figure 3.3.2.1.4 restriction digest of pAAV-IRES-hrGFP-ΔN-Tcf4 
Table 3.3.2.1.9 Sample description of figure 3.3.2.1.4 
Sample number Sample details 
WtC Midiprep sample Tcf4wt Control. BamHI and XhoI, buffer B 
ΔN Midiprep sample ΔN-Tcf4 BamHI and XhoI, buffer B 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
Subsequently, the restriction digests N1, N3 (see figure 3.3.2.1.3) and ΔN 
(N1: 30µl; N3: 40µl; ΔN: 40µl) were loaded on an agarose gel and the 
bands of Tcf4wt, ΔN-Tcf4 and VP16-ΔN-Tcf4 are cut successfully out of 
the gel according to 5.15.5 (see figure 3.3.2.1.5 and table 3.3.2.1.10). 
Subsequently, the DNA was extracted according to 5.15.5 and 2µl 
samples are checked on a 1% agarose gel (see figure 3.3.2.1.6 and table 
3.3.2.1.11). The DNA amount of each sample was estimated by 
comparing the band intensity with those of the used markers and 
measured with Nanodrop (see figure 5.12.4.1 Lambda 3 marker, 48502bp 
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and figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range). The 
estimated DNA amounts are depicted in table 3.3.2.1.12. After that a 
phosphatase treatment was done with the gel extracted samples according 
to 5.15.2. 2µl 0.001u/µl CIAP dilution (1:1000) was used for the 
phosphatase reaction mix at the Tcf4wt gel extracted sample. 1µl 
0.001u/µl CIAP dilution was used for phosphatase reaction mix at the 
ΔN-Tcf4 gel extracted sample and the VP16-ΔN-Tcf4 gel extracted 
sample. 
λM E1                    E2                    E3  MR
1904
λM E1        E2       E3   MR
excisions
 
Figure 3.3.2.1.5 Gel excision of Tcf4wt, ΔN-Tcf4 and VP16-ΔN-Tcf4: 
left photo: before gel excision; right photo: after gel excision 
 
Table 3.3.2.1.10 Sample description of figure 3.3.2.1.5 
Sample number Sample details 
E1 30µl N1 
E2 40µl ΔN 
E3 40µl N3 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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Figure 3.3.2.1.6 Gel extraction check 
 
Table 3.3.2.1.11 Sample description of figure 3.3.2.1.6 
Sample number Sample details 
C1 2µl N1 
Ex1 2µl E1 
C2 2µl ΔN 
Ex2 2µl E2 
C3 2µl N3 
Ex3 2µl E3 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
Table 3.3.2.1.12 Estimated DNA amounts of gel extracted samples 
ng/µl Sample details 
7 Tcf4wt gel extracted 
4 ΔN-Tcf4 gel extracted 
4 VP16-ΔN-Tcf4 gel extracted 
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Subsequently, 5.8ng phosphatase treated ΔN-Tcf4 sample was cloned into 
the pENTR/D-TOPO® according to 5.15.5. The resulting vector was 
transformed into 20µl commercial competent TOP10 E.coli (invitrogen) 
together with the pUC19 control (ampicillin resistance) and pENTR/D-
TOPO®-IIIC control (see 5.12.2.2). The transformation rate of these cells 
is 100 times higher (108 colonies/µg DNA) than self-made competent 
TOP10 E.coli. The resulting colony numbers are listed in table 3.3.2.1.13. 
The transformation rates are in table 3.3.2.1.14. Much more colonies 
could be gained at this transformation of a TOPO® cloning reaction if you 
compare the results of table 3.3.2.1.13 with those of table 3.3.2.1.3. The 
pENTR-IIIC control colony numbers of table 3.3.2.1.13 dropped 
significantly in comparison to table 3.3.2.1.3. 
Table 3.3.2.1.13 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control 137 Lawn 
pENTR-IIIC control 0 14 
pENTR-ΔN-Tcf4 0 42 
 
Table 3.3.2.1.14 Transformation rates 
Plate Colony numbers at 1µg 
pUC19 1:50 dilution (20pg) 6850000 
pENTR-IIIC rest (1ng) 14000 
pENTR- ΔN-Tcf4 rest (5.8ng) 7224 
 
4 colonies of the pENTR/D-TOPO®-ΔN-Tcf4 rest plate were picked and 
shaken at 200 rpm at 37°C overnight. Next day the DNA were isolated by 
miniprep and analyzed by electrophoresis. The expected fragments of the 
EcoRI and EcoRV restriction digest check are in table 3.3.2.1.7. The 
results are in figure 3.3.2.1.7 and table 3.3.2.1.15. 
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Figure 3.3.2.1.7 Digest of first production attempt of pENTR/D-
TOPO-ΔN-Tcf4 
 
Table 3.3.2.1.15 Sample description of figure 3.3.2.1.7 
Sample number Sample details 
T1/1 pENTR/D-TOPO®-ΔN-Tcf4 colony1 EcoRV, buffer B 
T1/2 pENTR/D-TOPO®-ΔN-Tcf4 colony1 EcoRI, EcoRV, buffer B 
T2/1 pENTR/D-TOPO®-ΔN-Tcf4 colony2 EcoRV, buffer B 
T2/2 pENTR/D-TOPO®-ΔN-Tcf4 colony2 EcoRI, EcoRV buffer B 
T3/1 pENTR/D-TOPO®-ΔN-Tcf4 colony3 EcoRV, buffer B 
T3/2 pENTR/D-TOPO®-ΔN-Tcf4 colony3 EcoRI, EcoRV, buffer B 
T4/1 pENTR/D-TOPO®-ΔN-Tcf4 colony4 EcoRV, buffer B 
T4/2 pENTR/D-TOPO®-ΔN-Tcf4 colony4 EcoRI, EcoRV, buffer B 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
There were only bands at 2500bp in figure 3.3.2.1.7. Thus the samples 
only included empty pENTR/D-TOPO® vectors. 18 colonies of the 
pENTR/D-TOPO®-ΔN-Tcf4 rest plate were picked again in order to find 
vectors with insert. Next day samples T5-T13 were pooled in one 
miniprep and samples T14-T22 in another one. 400µl of each overnight 
culture were taken in order to gain 2 pooled miniprep samples. The STET 
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boiling plasmid miniprep was used for this step (see 5.12.3). After that the 
2 miniprep samples were analyzed by EcoRI and EcoRV restriction 
digests and subsequent electrophoresis. These digests gave very strange 
results. Subsequently, DNA was isolated from the T5-T22 samples by 
STET minipreps, digested with EcoRI (10xbuffer H, Roche) and analyzed 
by electrophoresis. 
Additionally, a streak of pENTR-1A vector stock was done and 2 colonies 
were picked and cultivated in 6ml LB + kanamcyin overnight culture. 
Again DNA was isolated by STET minipreps from these 2 pENTR-1A 
samples, digested with BamHI (10x buffer B, Roche) and analyzed by 
electrophoresis.  
The subsequent gel photos of the digests are in figure 3.3.2.1.8, figure 
3.3.2.1.9, figure 3.3.2.1.10 and table 3.3.2.1.16. 
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Figure 3.3.2.1.8 Restriction digests of T5-T12 
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Figure 3.3.2.1.9 Restriction digests of T13-T18 
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Figure 3.3.2.1.10 Restriction digests of T19-T2 and pENTR-1A 
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Table 3.3.2.1.16 sample description of figure 3.3.2.1.8-10 
Sample number Sample details 
X5-X22 Sample T5-T22, EcoRI, buffer H 
C5 Sample T5, no restriction enzymes 
C10 Sample T10, no restriction enzymes 
C14 Sample T14, no restriction enzymes 
C20 Sample T20, no restriction enzymes 
XA pAAV-IRES-hrGFP-deltaN-Tcf4, EcoRI, buffer H 
CA pAAV-IRES-hrGFP-deltaN-Tcf4, no restriction enzymes 
XP1 pENTR-1A colony 1, BamHI, buffer B 
XP2 pENTR-1A colony 2, BamHI, buffer B 
CP1 pENTR-1A colony 1, no restriction enzymes 
CP2 pENTR-1A colony 2, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
X5-X22 did not give positive results which would be at 4297bp (see table  
3.4.1.16 ) . Positive samples could not be detected. Subsequently, the 
samples were classified in 3 groups. Group 1 had bands at 2500bp and 
1900bp (see X20, X12, X15 and X18). Group 2 had bands at 3000bp and 
2000bp (see X5-X11, X14, X21 and X22). Group 3 had bands at 2000 
(see X16, X17 and X19). 1 sample was chosen from each of the 3 groups: 
T17, T15 and T11. 2µl of these samples were digested with NruI (fast 
digest buffer) and analysed with electrophoresis (see figure 3.3.2.1.11 and 
table 3.3.2.1.17). No positive constructs could be detected. The bands 
were at 2500bp and below that. Thus they were empty pENTR/D-TOPO® 
vectors and fragments of those. Therefore the TOPO® cloning failed and 
it was decided to use a different pENTR vector. 
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Figure 3.3.2.1.11 NruI digest of T17, T15 and T11 
Table 3.3.2.1.17 Sample description of figure 3.3.2.1.11 
Sample number Sample details 
L1 
L2 
Sample T17, NruI, fast digest buffer 
Sample T15, NruI, fast digest buffer 
L3 Sample T11, NruI, fast digest buffer 
L4 Sample T17, no restriction enzymes 
L5 Sample T15, no restriction enzymes 
L6 Sample T11, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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3.3.2.2 pENTR-1A vector cloning 
It was tried to clone the Tcf4wildtype, ΔN-Tcf4 and VP16-ΔN-Tcf4 
fragments into the pENTR-1A vector (see figure 3.3.2.2.1). Both pENTR-
1A samples of figure 3.3.2.1.10 had bands at 2700bp (see XP1 and XP2) 
which were expected. It was estimated that pENTR-1A colony 2 sample 
had 20ng/µl according to the gel photo. 
 
Figure 3.3.2.2.1 pENTR-1A vector 
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Subsequently, 2 different methods are tried to clone ΔN-Tcf4 into the 
pENTR-1A vector. 
The first method(“quick method”): 
1µl pENTR-1A (20ng) and 1µl pAAV-IRES-hrGFP- ΔN-Tcf4 sample 
(200ng) were digested together with BamHI and XhoI in one 1.5ml 
Eppendorf tube and analysed by electrophoresis (see figure 3.3.2.2.2 and 
table 3.3.2.2.1). Subsequently, 5µl of the combined digest was ligated 
according to 5.16.2 and bacteria transformed according to 5.16.3 with 
pUC19 control (ampicillin resistance) and pENTR/D-TOPO®-IIIC 
control. This method failed for the ΔN-Tcf4 construct, while the pUC19 
control had a transformation efficiency of 1530000 colonies/µg. The 
restriction digest of figure 3.3.2.2.2 showed that the restriction enzymes 
do not work properly and that the DNA amount was too low. 
 
The second method (“sophisticated method”): 
pAAV-IRES-hrGFP- ΔN-Tcf4 sample (200ng/µl) was diluted 1:10 in 
order to have equal concentrations with pENTR-1A colony 2 sample. 
Both constructs were digested with 1µl BamHI and 1µl XhoI. The large 
double digests included 200ng DNA of each construct in 50µl reaction 
mix. These digests were analysed with electrophoresis (see figure 
3.3.2.2.2 and table 3.3.2.2.1). 
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Figure 3.3.2.2.2 pENTR-1A cloning digests 
 
Table 3.3.2.2.1 Sample description of figure 3.3.2.2.2 
Sample number Sample details 
A1 
A2 
pENTR-1A colony2, BamHI, buffer B 
pAAV-IRES-hrGFP- ΔN-Tcf4, BamHI, buffer B 
A3 pENTR-1A colony2 sample, XhoI, buffer B 
A4 pAAV-IRES-hrGFP- ΔN-Tcf4, XhoI, buffer B 
A5 pENTR-1A colony2 sample, BamHI, XhoI, buffer B 
A6 
A7 
A8 
A9 
 
A10 
pAAV-IRES-hrGFP- ΔN-Tcf4, BamHI, XhoI, buffer B 
pENTR-1A colony2, no restriction enzymes 
pAAV-IRES-hrGFP- ΔN-Tcf4, no restriction enzymes 
pENTR-1A colony2, pAAV-IRES-hrGFP- ΔN-Tcf4, BamHI, 
XhoI, buffer B 
pENTR-1A colony2, pAAV-IRES-hrGFP- ΔN-Tcf4,  
no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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The digests of pENTR-1A cloning did not work properly. Digestion 
products in lanes A1-A3 displayed the bands that had been expected. Thus 
the restriction enzyme XhoI worked clearly in A3 but it did not in A4. The 
double digest with BamHI and XhoI shown in A5 produced a lower 
molecular weight band as expected. 450bp were removed from the 
2700bp pENTR-1A vector. The double digest of the construct A6 resulted 
in a band at 5000bp that represents the pAAV-IRES-hrGFP without the 
ΔN-Tcf4 insert. There was a weak band at 7000bp which indicated that 
either the BamHI or XhoI cut was incomplete. On the gel a weak band 
could be detected at 1700bp representing the ΔN-Tcf4. In lane A8 the 
uncut pAAV-IRES-hrGFP- ΔN-Tcf4 could be seen. In lane A9 very weak 
bands were observed which showed pAAV-IRES-hrGFP without the ΔN-
Tcf4 insert and the smaller pENTR-1A but ΔN-Tcf4 alone could not be 
detected. The reason for that could be that only 1µl of the quick method 
digest was loaded on the gel.  
The digests of the sophisticated method of pENTR-1A was adapted: 
pENTR-1A colony glycerol stock was picked and the DNA was extracted 
by midiprep (result for aliquot 1: 220ng/µl). 5µg of both constructs were 
double digested with 3µl BamHI (Fermentas, #ER0051, 10u/µl) and 3µl 
XhoI (Fermentas, #ER0691, 10u/µl) in separate 50µl reaction mix. 
Additionally, 200ng of pENTR-1A were double digested in a 10µl 
reaction mix. 600ng of pAAV-IRES-hrGFP- ΔN-Tcf4 was digested with 
the same 10µl double digest. 200ng and 600ng were digested with 5u of 
each restriction enzyme. Analysis depicted in figure 3.3.2.2.3 and table 
3.3.2.2.2. M1 and M2 seemed to be completely digested, while M5 and 
M6 were not totally digested. Both 5µg DNA digests were only partially 
cut. This can be explained by the used units of the restriction enzymes. 
The enzyme activity of BamHI and XhoI are defined: 1u cuts 1µg λ DNA 
at 37°C for 1hour. Thereby, BamHI has 5 restriction sites and XhoI 1 
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restriction site in the λ phage genome. Thus BamHI has a 5fold restriction 
enzyme activity in comparison to XhoI. If this unit definitions are related 
to the pAAV-IRES-hrGFP-ΔN-Tcf4 construct (approx.7000bp) and the 
pENTR-1A vector (2700bp) XhoI needs more units in order to cut 
completely than it is used in the restriction digest of figure 3.3.2.2.3 but 
BamHI is used in excess. 35u of XhoI has to be used at the pAAV-IRES-
hrGFP-ΔN-Tcf4 construct and 90u for pENTR-1A rather than 30u. M9 
and M10 were totally digested and were used for the subsequent ligation 
reaction.  
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Figure 3.3.2.2.3 BamHI and XhoI digests of 5µg pENTR-1A and 
pAAV-IRES-hrGFP-ΔN-Tcf4 
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Table 3.3.2.2.2 Sample description of figure 3.3.2.2.3 
Sample number Sample details 
M1 
M2 
pAAV-IRES-hrGFP- ΔN-Tcf4, BamHI, buffer B 
pAAV-IRES-hrGFP- ΔN-Tcf4, XhoI, buffer B 
M3 pAAV-IRES-hrGFP- ΔN-Tcf4, no restriction enzymes 
M4 pAAV-IRES-hrGFP- ΔN-Tcf4,BamHI, XhoI, buffer B, 5µg DNA 
M5 pENTR-1A colony2 aliquot1, BamHI, buffer B 
M6 
M7 
M8 
M9 
 
M10 
pENTR-1A colony2 aliquot1, XhoI, buffer B 
pENTR-1A colony2 aliquot1, no restriction enzymes 
pENTR-1A colony2 aliquot1, BamHI, XhoI, buffer B, 5µg DNA  
pENTR-1A colony2 aliquot1, BamHI, XhoI, buffer B, 220ng 
DNA 
pAAV-IRES-hrGFP- ΔN-Tcf4,BamHI, XhoI, buffer B, 600ng 
DNA 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
1µl M9 (22ng) and 4µl M10 (240ng) were ligated according to 5.16.2 and 
bacteria transformed according to 5.12. Negative ligation controls of M9 
and M10 alone as well as 1ng pUC19 and 1ng pEGFP-C1 (kanamycin 
resistance, Clontech) as positive control were also used for 
transformation. The results are in tables 3.3.2.2.3 and 3.3.2.2.4. The 
ligation was inefficient. The pEGFP-1C positive control showed expected 
transformation rates and this fact indicated that kanamycin plates were not 
the problem of the low transformation rates. The 1 clone of the pENTR-
1A- ΔN-Tcf4 was picked and cultivated overnight. A streak of the picked 
clone was done. A clone was picked from the streak and cultivated 
overnight. The DNA of the streak clone sample was isolated by miniprep 
with column according to 5.12.3. The DNA concentration was very low at 
25ng/µl. 4µl of the sample was digested by BamHI and XhoI and 
analysed by electrophoresis. Bands could not be detected on the gel. 
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Table 3.3.2.2.3 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control 6 Lawn 
pEGFP-C1 
Vector negative control 
Insert negative control 
30 Approx.1000 
0 
0 
pENTR-1A-ΔN-Tcf4 0 1 
 
Table 3.3.2.2.4 Transformation rates 
Plate Colony numbers at 1µg 
pUC19 1:50 dilution (20pg) 300000 
GFP-C1 1:50 (20pg) 1500000 
GFP-C1 Rest (1ng) 1000000 
 
In order to identify the supposed problem with the ligase, 0.5µl T4 DNA 
ligase (Fermentas, 30u/µl) and the 10x T4 DNA Ligase Buffer of another 
lab (test 1) was used to ligate 10ng pAAV-IRES-hrGFP- ΔN-Tcf4 which 
was digested with XhoI. Additionally, the same restriction digest sample 
was ligated with T4 DNA ligase (Fermentas, 5u/µl) of the Prof.Holzmann 
lab in combination with 10x T4 DNA Ligase Buffer of the other lab (test 
2). As a control the sample mix without ligase was used (ligation negative 
control). See the results in table 3.3.2.2.5 and table 3.3.2.2.6. 
 
Table 3.3.2.2.5 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control 31  
Test1 
Test2 
2 
55 
71 
Approx.1000 
Ligation negative control  5 
   
Table 3.3.2.2.6 Transformation rates 
Plate Colony numbers at 1µg 
pUC19 1:50 dilution (20pg) 1550000 
Test1 1:50 (200pg) 
Test1 Rest (10ng) 
Test2 1:50 (200pg) 
Test2 Rest (10ng) 
10000 
7100 
275000 
100000 
Ligation negative control (10ng) 500 
 
65 
The ligation control experiment showed that the ligase buffer of the 
Prof.Holzmann caused problems. A possible explanation was that the 
ATP was decayed. 
According to the results of the ligation control experiment 2µl pENTR-1A 
vector (220ng/µl) was double digested with 0.5µl BamHI and 0.5µl XhoI 
in a 10µl digest. Subsequently, 3µl pAAV-IRES-hrGFP- ΔN-Tcf4 
(200ng/µl) was digested in the same manner. 5µl of the vector digest was 
dephosphorylated with1µl CIAP dilution (0.01u/µl) according to 5.16.2. 
After that 3 different ligations were done according to 5.16.2 successful 
ligation mix. α ligation included 1µl desphosphorylated pENTR-1A digest 
(20ng) and 4µl pAAV-IRES-hrGFP- ΔN-Tcf4 digest (240ng). β ligation 
had the same composition like α ligation excepting 1µl phosphorylated 
pENTR-1A digest (44ng) instead of the dephosphorylated vector.  
γ ligation was an adaption of α ligation: 2µl of the vector and 6µl of the 
insert were included. The ligation samples were transformed in competent 
E.coli cells and the results are in table 3.3.2.2.7 and 3.3.2.2.8. 1ng pUC19 
was heat shocked for 35 and 90 seconds as controls in addition to the 1ng 
pEGFP-C1 control (kanamycin resistance, Clontech).  
Only the β ligation was successful and produced colonies. Interestingly, 
the dephosphorylated samples failed. It could be that the 
dephosphorylation procedure destroyed the sticky ends resulting in an 
inhibition of ligation. 4 colonies of the β ligation were picked from the 
rest plate and cultivated overnight. Next day STET miniprep was done to 
isolate DNA. The yield was between 70 and 250ng/µl. Subsequently, 2µl 
miniprep samples were digested with 0.5µl BamHI alone and the same 
amount of enzyme restriction enzyme was also used in combination with 
0.5µl XhoI (buffer B). The results are summarized in figure 3.3.2.2.4 and 
table 3.3.2.2.9. The expected fragments are in table 3.3.2.2.10. 
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Table 3.3.2.2.7 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control 35s 
pUC19 control 90s 
GFP-C1 control 
Uncountable 
Uncountable 
24 
 
α ligation 
β ligation 
0 
6 
0 
116 
γ ligation 0 0 
 
Table 3.3.2.2.8 Transformation rates 
Plate Colony numbers at 1µg 
GFP-C1 control (1ng) 1200000 
β ligation (10ng) 1:50 aliquot 30000 
β ligation (10ng) 11600 
 
 
Figure 3.3.2.2.4 restriction digest for identification of  
pAAV-IRES-hrGFP- ΔN-Tcf4 clones 
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Table 3.3.2.2.9 Sample description of figure 3.3.2.2.4 
Sample number Sample details 
Z1 
Z2 
pENTR-1A- ΔN-Tcf4 colony 1, BamHI 
pENTR-1A - ΔN-Tcf4 colony1, BamHI, XhoI 
Z3 pENTR-1A - ΔN-Tcf4 colony 1, no restriction enzymes 
Z4 pENTR-1A- ΔN-Tcf4 colony 2, BamHI 
Z5 pENTR-1A - ΔN-Tcf4 colony 2, BamHI, XhoI 
Z6 
Z7 
Z8 
Z9 
Z10 
Z11 
Z12 
pENTR-1A - ΔN-Tcf4 colony 2, no restriction enzymes 
pENTR-1A- ΔN-Tcf4 colony 3, BamHI 
pENTR-1A - ΔN-Tcf4 colony 3, BamHI, XhoI 
pENTR-1A - ΔN-Tcf4 colony 3, no restriction enzymes 
pENTR-1A- ΔN-Tcf4 colony 4, BamHI 
pENTR-1A - ΔN-Tcf4 colony 4, BamHI, XhoI 
pENTR-1A - ΔN-Tcf4 colony 4, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
Table 3.3.2.2.10 Expected fragments for BamHI and XhoI digests 
Restriction enzymes Constructs and fragments (bp) 
BamHI Vector + ΔN-Tcf4: 3995  
BamHI and XhoI Vector + ΔN-Tcf4: 1728; 2267 
 
pENTR-1A- ΔN-Tcf4 colony 2 and colony 4 samples showed the correct 
bands as expected. Colony 1 showed only weak bands which were also 
correct. Colony 3 had bands which were shifted too higher molecular 
weight and thus they were incorrect. 
Subsequently, BamHI and XhoI double digests of 600ng pAAV-IRES-
hrGFP-VP16-ΔN-Tcf4 and pAAV-IRES-hrGFP-Tcf4wt and 440ng 
pENTR-1A were obtained similar to the previous procedure with pAAV-
IRES-hrGFP- ΔN-Tcf4. After that the samples were ligated and 
transformed according to the same procedure above. The results are listed 
in table 3.3.2.2.11 and table 3.3.2.2.12. 
 
Table 3.3.2.2.11 Colony numbers 
Sample 1:50 dilution Rest 
pUC19 control Uncountable Uncountable 
VP16 ligation 28 Approx.1000 
Wt ligation 86 Approx. >1000 
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Table 3.3.2.2.12 Transformation rates 
Plate Colony numbers at 1µg 
VP16 ligation (22ng) 1:50 aliquot 63636 
Wt ligation (22ng) 1:50 aliquot 195454 
 
The yield of colonies was much higher than in the previous β ligation. 2 
colonies were picked from each of the 1:50 aliquot plates of VP16 ligation 
and Wt ligation and cultivated overnight. Subsequently, minipreps with 
column were done with the samples according to 5.12.3. Additionally, an 
overnight culture was cultivated from the β ligation glycerine stock of 
pENTR-1A- ΔN-Tcf4 colony 4 and a subsequent miniprep with column 
was done. The yields of the miniprep samples were between 60 and 
100ng/µl. After that 2µl of each miniprep sample was tested with 3 
different restriction digests as above. The results are shown in figure 
3.3.2.2.5, figure 3.3.2.2.6 and table 3.3.2.2.13. The expected fragments of 
the digests are listed in table 3.3.2.2.14. 
 
Figure 3.3.2.2.5 restriction digests of VP16 ligation and wt ligation 
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Figure 3.3.2.2.6 restriction digests of VP16 ligation and wt ligation  
 
Table 3.3.2.2.13 Sample description of figure 3.3.2.2.5-6 
Sample number Sample details 
K1 
K2 
pENTR-1A-Tcf4wt colony 1, XhoI 
pENTR-1A -Tcf4wt colony1, BamHI, XhoI 
K3 pENTR-1A -Tcf4wt colony 1, no restriction enzymes 
K4 pENTR-1A-Tcf4wt colony 2, XhoI 
K5 pENTR-1A -Tcf4wt colony 2, BamHI, XhoI 
K6 
K7 
K8 
K9 
K10 
K11 
K12 
K13 
K14 
K15 
pENTR-1A -Tcf4wt colony 2, no restriction enzymes 
pENTR-1A-VP16-ΔN-Tcf4 colony 1, XhoI 
pENTR-1A-VP16-ΔN-Tcf4 colony 1, BamHI, XhoI 
pENTR-1A –VP16-ΔN-Tcf4 colony 1, no restriction enzymes 
pENTR-1A-VP16-ΔN-Tcf4 colony 2, XhoI 
pENTR-1A-VP16-ΔN-Tcf4 colony 2, BamHI, XhoI 
pENTR-1A-VP16-ΔN-Tcf4 colony 2, no restriction enzymes 
pENTR-1A-ΔN-Tcf4 colony 4, XhoI 
pENTR-1A-ΔN-Tcf4 colony 4, BamHI, XhoI 
pENTR-1A-ΔN-Tcf4 colony 4, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
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Table 3.3.2.2.14 Expected fragments for BamHI and XhoI digests 
Restriction enzymes Constructs and fragments (bp) 
XhoI Vector + Tcf4wt: 4085  
Vector + VP16- ΔN-Tcf4: 4244 
BamHI and XhoI Vector + Tcf4wt: 1818; 2267 
Vector + VP16-ΔN-Tcf4: 1977; 2267 
 
Both colonies of pENTR-1A-Tcf4wt and pENTR-1A-VP16-ΔN-Tcf4 
yielded the expected fragments in the digest. The miniprep of pENTR-1A-
ΔN-Tcf4 colony 4 also produced weak bands that were not expected 
indicating minimal traces of another product. In order to gain pure 
pENTR-1A-ΔN-Tcf4 bacteria from the glycerol stock were streaked onto 
a plate to produce single colonies that were picked and DNA obtained by 
a miniprep with column according to 5.12.3 with the concerning overnight 
cultures. The 2 miniprep samples were digested with BamHI and XhoI as 
above. Additionally, double digests of pENTR-1A-Tcf4wt colony 1 and 
pENTR-1A-VP16-ΔN-Tcf4 colony 1 were produced. The samples were 
analyzed by gel electrophoresis. The results are depicted in figure 
3.3.2.2.7 and table 3.3.2.2.15. The expected fragments are listed in table 
3.3.2.2.10 and 3.3.2.2.14. 
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λM      µ1     µ2     µ3     µ4     µ5    µ6      µ7    µ8    MR    λM
1500
2000
2500
3000
4000
5000
6000
8000
5148
20272027
5148
Figure 3.3.2.2.7 restriction digests of the streak samples 
 
Table 3.3.2.2.15 Sample description of figure 3.3.2.2.7 
Sample number Sample details 
µ1 
µ2 
pENTR-1A-Tcf4wt colony 1, BamHI, XhoI 
pENTR-1A-VP16-ΔN-Tcf4 colony 1, BamHI, XhoI 
µ3 pENTR-1A-ΔN-Tcf4 colony 4 streak colony1 BamHI, XhoI 
µ4 pENTR-1A-ΔN-Tcf4 colony 4 streak colony1, XhoI 
µ5 pENTR-1A-ΔN-Tcf4 colony 4 streak colony1, no restriction 
enzymes 
µ6 
µ7 
µ8 
pENTR-1A-ΔN-Tcf4 colony 4 streak colony2 BamHI, XhoI 
pENTR-1A-ΔN-Tcf4 colony 4 streak colony2, XhoI 
pENTR-1A-ΔN-Tcf4 colony 4 streak colony2, no restriction 
enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
The predicted bands were obtained in all samples demonstrating that the 
constructs had the correct sequence and were suitable for construction of 
the adenoviral constructs. 
72 
See the resulting pENTR1A-insert clones in figures 3.3.2.2.8-10. 
 
Figure 3.3.2.2.8 pENTR1A-TCF4wt 
 
Figure 3.3.2.2.9 pENTR1A-deltaN-TCF4 
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Figure 3.3.2.2.10 pENTR1A-VP16-deltaN-TCF4 
 
 
 
 
 
 
 
 
 
 
 
74 
3.3.3 pAd/CMV/V5-DEST vector cloning: 
After pENTR cloning the inserts had to be recombined into the adenoviral 
expression vector pAd/CMV/V5-DEST™ vector (see figure 3.3.3.1) by 
the LR reaction. 
 
Figure 3.3.3.1 pAd/CMV/V5-DEST™ vector 
 
The Tcf4wt, ΔN-Tcf4, VP16-ΔN-Tcf4 inserts were flanked by attL1 and 
attL2 recombination sites of the pENTR1A vector and those sites were 
recombined into the pAd/CMV/V5-DEST™ vector (invitrogen, see figure 
3.3.3.1) by Gateway® LR Clonase™ II reaction (invitrogen) according to 
5.17. The LR reaction is depicted in figure 3.3.3.2. 
 
 
Figure 3.3.3.2 overview of LR reaction 
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3µl pENTR-1A-Tcf4wt colony1 and 3µl pENTR-1A –VP16-ΔN-Tcf4 
colony1 miniprep samples (about 150ng) were recombined with 1µl 
pAd/CMV/V5-DEST™ vector in a half mix according to 5.17. 2µl 
pENTR-1A-ΔN-Tcf4 colony 4 streak colony2 was also combined with the 
destination vector in a full mix according to 5.17. The resulting half 
gateway mixes samples were transformed in commercial TOP10 E.coli 
according to 5.12.2. Additionally, half of the mix of pAd/CMV/V5-
DEST- ΔN-Tcf4 was transformed in Chinese hyper-competent cells 
according to 5.12.2. pUC19 controls were used for both competent cell 
types. The results are in table 3.3.3.1 and table 3.3.3.2.  
2 colonies per plate were picked and cultivated in 7ml Chinese SOC/AMP 
overnight. Subsequently, DNA was obtained by miniprep with column. 
 
Table 3.3.3.1 Colony numbers 
Sample 1:50 dilution 1:100 dilution Rest 
pUC19  Chinese  50  
PUC19 commercial Several 100  Uncountable 
Tcf4wt 
VP16 
ΔTcf4 Chinese 
ΔTcf4 commercial 
  7 
16 
6 
22 
 
Table 3.3.3.2 Transformation rates 
Plate Colony numbers at 1µg 
pUC19 Chinese (10pg) 1:100 
pUC19 bought (20pg) 1:50 
Tcf4wt (150ng) 
VP16 (150ng) 
5000000 
More than 10000000 
46 
105 
ΔTcf4 Chinese 
ΔTcf4 bought 
39 
145 
 
4µl of the miniprep samples and 2µl of the empty pAd/CMV/V5-DEST™ 
vector were digested with 0.5µl XhoI and buffer H (Roche) and then 
analyzed by electrophoresis. The results are shown in figure 3.3.3.3, 
figure 3.3.3.4 and table 3.3.3.3. The expected fragments are in table 
3.3.3.4. 
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Figure 3.3.3.3 XhoI digest of LR-reaction samples 
 
 
Figure 3.3.3.4 XhoI digest of LR-reaction samples 
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Table 3.3.3.3 Sample description of figure 3.3.3.3-4 
Sample number Sample details 
U1 
U2 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 Chinese, XhoI 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 Chinese, no restriction 
enzymes 
U3 pAd/CMV/V5-DEST- ΔN-Tcf4 colony2 Chinese, XhoI 
U4 pAd/CMV/V5-DEST- ΔN-Tcf4 colony2 Chinese, no restriction 
enzymes 
U5 pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 commercial cells, XhoI 
U6 
 
U7 
U8 
 
U9 
U10 
U11 
U12 
U13 
U14 
 
U15 
U16 
 
U17 
U18 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 commercial cells,  
no restriction enzymes 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony2 commercial cells, XhoI 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 commercial cells,  
no restriction enzymes 
pAd/CMV/V5-DEST-Tcf4wt colony1, XhoI 
pAd/CMV/V5-DEST-Tcf4wt colony1, no restriction enzymes 
pAd/CMV/V5-DEST-Tcf4wt colony2, XhoI 
pAd/CMV/V5-DEST-Tcf4wt colony2, no restriction enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony1, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony1, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony2, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony2, no restriction 
enzymes 
pAd/CMV/V5-DEST, XhoI 
pAd/CMV/V5-DEST, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
Table 3.3.3.4 Expected fragments for XhoI digest 
Construct fragments (bp) 
pAd/CMV/V5-DEST-ΔN-Tcf4 2699; 2698; 2466; 1445; 595; 14502; 
11832 
pAd/CMV/V5-DEST-Tcf4wt 2789; 2698; 2466; 1445; 595; 14502; 
11832 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 2948; 2698; 2466; 1445; 595; 14502; 
11832 
pAd/CMV/V5-DEST 485; 5846; 2466; 1445; 595; 14502; 
11347 
 
The fragments of pAd/CMV/V5-DEST- ΔN-Tcf4 and pAd/CMV/V5-
DEST-Tcf4wt samples and of the empty pAd/CMV/V5-DEST were as 
expected. pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 produced different 
fragments as expected. 
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Subsequently, 7ml LB/AMP cultures were obtained from pAd/CMV/V5-
DEST-ΔN-Tcf4 colony2 Chinese and colony 1commercial cells samples. 
The same was done with pAd/CMV/V5-DEST-Tcf4wt colony1. In order 
to identify bacteria containing the correct pAd/CMV/V5-DEST-VP16- 
ΔN-Tcf4 construct 8 colonies were picked. Next day STET boiling 
plasmid miniprep were performed and the samples were checked with 
XhoI as above. The results are summarized in figure 3.3.3.5, figure 3.3.3.6 
and table 3.3.3.5. 
79 
 
 
Figure 3.3.3.5 XhoI digest of different  
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 clones 
 
 
Figure 3.3.3.6 XhoI digest of different  
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 clones 
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Table 3.3.3.5 Sample description of figure 3.3.3.5-6 
Sample number Sample details 
Ω1 
Ω2 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 commercial cells, XhoI 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1 commercialt cells,  
no restriction enzymes 
Ω3 pAd/CMV/V5-DEST-Tcf4wt colony1, XhoI 
Ω4 pAd/CMV/V5-DEST-Tcf4wt colony1, no restriction enzymes 
Ω5 pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony3, XhoI 
Ω6 
 
Ω7 
Ω8 
 
Ω9 
Ω10 
 
Ω11 
Ω12 
 
Ω13 
Ω14 
 
Ω15 
Ω16 
 
Ω17 
Ω18 
 
Ω19 
Ω20 
 
Ω21 
Ω22 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony3, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony4, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony4, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony5, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony5, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony6, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony6, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony7, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony7, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony8, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony8, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony9, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony9, no restriction 
enzymes 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony10, XhoI 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony10, no restriction 
enzymes 
pAd/CMV/V5-DEST, XhoI 
pAd/CMV/V5-DEST, no restriction enzymes 
λM Figure 5.12.4.1 Lambda 3 marker 
MR Figure 5.12.4.2 Mass Ruler™ DNA Ladder High Range 
 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony3 and 4 did not produce the 
predicted bands but colony5 -10 digests resulted in the expected bands. 
pAd/CMV/V5-DEST- ΔN-Tcf4 colony1commercial cells and 
pAd/CMV/V5-DEST-Tcf4wt colony1 had bands as predicted. 
Figure 3.3.3.5 and figure 3.3.3.6 also proved that 3 different adenoviral 
constructs were produced. 
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Finally, glycerol stocks were made of bacteria habouring pAd/CMV/V5-
DEST- ΔN-Tcf4 colony1 bought cells, pAd/CMV/V5-DEST-Tcf4wt 
colony1 and pAd/CMV/V5-DEST-VP16- ΔN-Tcf4 colony5 and DNA 
was isolated by midiprep. 
The constructed pAd/CMV/V5-DEST-insert vectors are shown in figure 
3.3.3.7-9. 
 
 
 
 
 
Figure 3.3.3.7 pAd/CMV/V5-Dest-TCF4wt 
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Figure 3.3.3.8 pAd/CMV/V5-Dest-deltaN-TCF4 
 
Figure 3.3.3.9 pAd/CMV/V5-Dest-VP16-deltaN-TCF4 
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3.3.4 Virus production in HEK293 cells 
The 3 pAd/CMV/V5-DEST-insert midiprep samples were digested with 
PacI and the plasmids were checked and precipitated according to 5.18. 
The results are depicted in figure 3.3.4.1-2 and table 3.3.4.1-2. The 
expected fragments of the PacI digest were 2074bp and about 34000bp. 
 
Figure 3.3.4.1 PacI digest 
Table 3.3.4.1 Sample description of figure 3.3.4.1 
Sample number Sample details 
P1 
P2 
pAd/CMV/V5-DEST-Tcf4wt, no restriction enzymes 
pAd/CMV/V5-DEST-Tcf4wt, PacI, before precipitation 
P3 pAd/CMV/V5-DEST-Tcf4wt, PacI, after precipitation 
P4 pAd/CMV/V5-DEST- ΔN-Tcf4, no restriction enzymes  
P5 pAd/CMV/V5-DEST- ΔN-Tcf4, PacI, before precipitation 
P6 
P7 
P8 
pAd/CMV/V5-DEST- ΔN-Tcf4, PacI, after precipitation 
pAd/CMV/V5-DEST-VP16- ΔN-Tcf4, no restriction enzymes 
pAd/CMV/V5-DEST- VP16-ΔN-Tcf4, PacI, before precipitation 
P9 pAd/CMV/V5-DEST- VP16-ΔN-Tcf4, PacI, after precipitation 
λM Figure 5.12.4.1 Lambda 3 marker 
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All digests showed clear bands at 2000bp as expected. Nanodrop 
measurements showed that pAd/CMV/V5-DEST- VP16-ΔN-Tcf4 had 
250ng/µl after precipitation and this was enough for transfection. 
pAd/CMV/V5-DEST-ΔN-Tcf4 and pAd/CMV/V5-DEST-Tcf4wt had 30-
50ng/µl yield after precipitation and these constructs were digested and 
precipitated again with higher yield (about 150-200ng/µl). Subsequently, 
the linearized adenoviral constructs were transfected into HEK293 cells 
according to 5.18. After 3 days the cells were cracked according to 5.18. 
A cytopathic effect could not be detected.  
It was decided to go on with the pAd/CMV/V5-DEST-ΔN-Tcf4. 
Subsequently, 100µl, 200µl and 400µl of the cracked sample were added 
to HEK293 cells in 6-well-plates and a cytopathic effect was observed at 
day 3 and at day4 the cells were cracked (passage 2). HEK293 cells were 
transfected with 500µl and 250µl lysate in 2*10cm Pds and a cytopathic 
effect was detected again at day 3. The plates were cracked separately 
(passage 3) and a standard PCR for pAd/CMV/V5-DEST-insert according 
to 5.18.6 was performed in order to prove that pAd/CMV/V5-DEST-ΔN-
Tcf4 was in the lysates. The expected PCR product lengths are listed in 
table 3.3.4.2. The PCR products were tested by electrophoresis (see figure 
3.3.4.2 and table 3.3.4.3). 
 
Table 3.3.4.2 PCR product lengths 
Constructs Lenghts 
pAd/CMV/V5-DEST-empty 
pAd/CMV/V5-DEST-VP16-ΔN-Tcf4 
pAd/CMV/V5-DEST- ΔN-Tcf4 
2368bps 
2168bps 
1919bps 
pAd/CMV/V5-DEST-Tcf4wt 2009bps 
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λM SP1    SP2    SP3  SP4   SP5  SP6     SP7     λM
5148
20272027
5148
1904 1904
 
Figure 3.3.4.2 Control PCR of pAd/CMV/V5-DEST-ΔN-Tcf4 virus 
 
 
Table 3.3.4.3 Sample description of figure 3.3.4.2 
Sample number Sample details 
SP1 
SP2 
SP3 
SP4 
NTC 
pAd/CMV/V5-DEST-empty control 
pAd/CMV/V5-DEST- VP16-ΔN-Tcf4 plasmid 
pAd/CMV/V5-DEST- ΔN-Tcf4 plasmid 
SP5 pAd/CMV/V5-DEST- ΔN-Tcf4 virus sample 500µl plate 
SP6 pAd/CMV/V5-DEST- ΔN-Tcf4 virus sample 250µl plate 
SP7 pAd/CMV/V5-DEST-Tcf4wt plasmid 
λM Figure 5.12.4.1 Lambda 3 marker 
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Additionally, a new PacI digest of pAd/CMV/V5-DEST-ΔN-Tcf4 was 
performed and precipitated as above. The yield was about 230ng/µl after 
precipitation. The digest was also analyzed with gel electrophoresis. The 
results are depicted in figure 3.3.4.3 and table 3.3.4.4. 
2µl λM S1               S2               S3  2µl λM 4µl λM   
5148
20272027
5148
3.3.4.3 pAd/CMV/V5-DEST-ΔN-Tcf4 PacI digest 
Table 3.3.4.4 Sample description of figure 3.3.4.3 
Sample number Sample details 
S1 
S2 
pAd/CMV/V5-DEST-ΔN-Tcf4, no restriction enzymes 
pAd/CMV/V5-DEST-ΔN-Tcf4, PacI, before precipitation 
S3 pAd/CMV/V5-DEST-ΔN-Tcf4, PacI, after precipitation 
λM Figure 5.12.4.1 Lambda 3 marker 
 
Subsequently, the transfection of the HEK293 cells were performed with 
10µl and 5µl of the precipitated PacI digest in 2 wells of a 6-well-plate 
according to 5.18. After 5 days the cells were cracked according to 5.18 
because a cytopathic effect might be observed. Subsequently, HEK293 
cells were transfected with 500µl and 250µl lysate in 2*10cm Pds but a 
cytopathic effect could not be detected after 7 days and the attempt was 
discarded. 
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The bands of figure 3.3.4.2 showed clearly that the HEK293-virus lysate 
contained the pAd/CMV/V5-DEST- ΔN-Tcf4 construct. Subsequently, 
3*10cm Pds with HEK293 cells were incubated with 100µl, 200µl and 
300µl HEK293-virus lysate of the 500µl plate (passage 3). After 24 hours 
a strong cytopathic effect could be observed and they were cracked. The 
propagation of viral particles needs at least 48 hours and thus the passage 
had to be repeated with a smaller amount of lysate. The repetition of the 
reinfection with 30µl HEK293-virus lysate of the 500µl plate (passage 3) 
causes a cytopathic effect after 24 hours again and they are cracked on the 
second day. 250µl of these passage 4 lysate were incubated on each 
2x15cm plates with 8x108  HEK293 cells. After 2 days a strong cytopathic 
effect was observed and the cells were cracked. Subsequently, the passage 
5 lysate was tested again with PCR according to 5.18.6. The expected 
PCR product lengths are listed in table 3.3.4.2. The PCR products were 
analysed by electrophoresis (see figure 3.3.4.4 and table 3.3.4.5) but no 
viral particles could be detected (see no band at SP5). 
λM SP1    SP2   SP3    SP4     SP5    SP6    λM
5148
20272027
5148
1904 1904
 
Figure 3.3.4.4 2nd control PCR of pAd/CMV/V5-DEST-ΔN-Tcf4 
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Table 3.3.4.5 Sample description of figure 3.3.4.4 and figure3.3.4.5 
Sample number Sample details 
SP1 
SP2 
SP3 
SP4 
NTC 
pAd/CMV/V5-DEST-empty control 
pAd/CMV/V5-DEST- VP16-ΔN-Tcf4 plasmid 
pAd/CMV/V5-DEST- ΔN-Tcf4 plasmid 
SP5 pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 5 in figure 3.4.1.34 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 in figure 3.4.1.35 
SP6 pAd/CMV/V5-DEST-Tcf4wt plasmid 
λM Figure 5.12.4.1 Lambda 3 marker 
 
The problem could be that the cytopathic effect was too strong and too 
early. This causes that most viral particles were delivered in the medium 
but they could not be harvested by the cracking procedure. 
After that 2x15cm Pds with HEK293 cells were reinfected with 30µl 
HEK293-virus lysate of the 500µl plate (passage 3) and a strong 
cytopathic effect could be observed at day 2. This new passage 4 was 
tested again with PCR according to 5.18.6 and analysed by 
electrophoresis (see figure 3.3.4.5 and table 3.3.4.5). Again virus DNA 
could not be detected. 
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λM SP1   SP2      SP3    SP4     SP5    SP6    λM
5148
20272027
5148
1904 1904
 
Figure 3.3.4.5 Passage 4 control PCR of pAd/CMV/V5-DEST-ΔN-
Tcf4 
 
Subsequently, 4x confluent 15cm Pds with HEK293 cells were reinfected 
with 15µl HEK293-virus lysate of the 500µl plate and the 250µl plate 
(passage 3) and a strong cytopathic effect could be observed at day 2. The 
cells were cracked on day 2 and day3. The medium became acidic on day 
3 (yellow color of the indicator). The cracked lysates and the medium 
supernatants were tested by the PCR according to 5.18.6 and analysed by 
electrophoresis (see figure 3.3.4.6 and table 3.3.4.6). 
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λM S1   S2    S3    S4    S5    S6    S7   S8  S9  S10    S11    S12    λM
5148
20272027
5148
1904 1904
 
Figure 3.3.4.6 New passage 4 control PCR of pAd/CMV/V5-DEST-
ΔN-Tcf4 
 
Table 3.3.4.6 Sample description of figure 3.3.4.6 
Sample number Sample details 
S1 
S2 
S3 
S4 
NTC 
pAd/CMV/V5-DEST- ΔN-Tcf4 plasmid 
pAd/CMV/V5-DEST- ΔN-Tcf4 passage 3 500µl plate lysate 
pAd/CMV/V5-DEST- ΔN-Tcf4 passage 3 250µl plate lysate 
S5 pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 lysate with 
passage 3 500µl lysate day 2 
S6 
 
S7 
 
S8 
 
S9 
 
S10 
 
S11 
 
S12 
 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 lysate with 
passage 3 250µl lysate day 2 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 medium with 
passage 3 500µl lysate day 2 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 medium with 
passage 3 250µl lysate day 2 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 lysate with 
passage 3 500µl lysate day 3 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 lysate with 
passage 3 250µl lysate day 3 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 medium with 
passage 3 500µl lysate day 3 
pAd/CMV/V5-DEST- ΔN-Tcf4 virus passage 4 medium with 
passage 3 250µl lysate day 3 
λM Figure 5.12.4.1 Lambda 3 marker 
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Viral particle could not be detected in all lysates but clear bands could be 
seen at the medium supernatant samples which supported the explanation 
that most viral particles were delivered into the medium. Passage 3 
samples did not show any bands although they were detected in figure 
3.3.4.2. This could indicate an error with the PCR. It could not be that 
passage 4 medium supernatant had bands for the viral particles but 
passage 3 did not. 
After that a new PCR according to 5.18.6 was done with passage 2, 
passage 3 of the 500µl plate and of the 250µl plate and with all new 
passage 4 lysates of day 2 and day 3. 20µl of each lysate was mixed with 
180µl 1xTE. The PCR products were analysed by electrophoresis but no 
virus could be detected (data not shown). 
Subsequently, 2x10 cm Pds with HEK293 cells were reinfected with 2µl 
lysate and 100µl medium supernatant of passage 4 lysate of the 500µl 
plate day 2. The lysate gave a clear and strong cytopathic effect after 2 
days. The medium of passage 4 has already shown the correct viral band 
at the PCR (see figure 3.3.4.6). Thus 15x15 cm Pds with 107 HEK293 
cells were transfected with 2µl of the concerning passage 4 lysate and 
after 2 days they were cracked. The virus was isolated by 
ultracentrifugation according to 5.18.7. There were 4 bands and the lowest 
of them was the largest (see figure 3.3.4.7).  
The highest band, the 2 bands in the middle and the lowest band were 
collected as 3 different aliquots which were stored at -80°C. They are 
called from up till down band1, band2 and band3. The upper bands might 
be premature viral particles. The lowest band seemed to be the mature 
viral particles  
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Figure 3.3.4.7 Virus bands after ultracentrifugation 
 
Subsequently, the 3 bands samples were analyzed with virus titration 
according to 5.18.8.  
Then the virus titers were calculated: 
Band 1 had 31600 infectious units and band 2 showed 47400. Thus the 
upper bands included a tiny number of infectious particles which 
supported the explanation above. Band3 had 15800000/µl infectious units. 
The controls virus titers were as expected. 
In order to prove that band1-band3 had the correct virus a control PCR 
according to 5.18.6 was performed and analysed by electrophoresis (see 
figure 3.3.4.8 and table 3.3.4.7) 
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λM S1   S2       S3      S4        S5      S6    S7       λM
5148
2027
2027
5148
1904
1904
Figure 3.3.4.8 Control PCR with isolated bands 
Table 3.3.4.7 Sample description of figure 3.3.4.8 
Sample number Sample details 
V1 
V2 
V3 
V4 
NTC 
pAd/CMV/V5-DEST- VP16-ΔN-Tcf4 plasmid 
pAd/CMV/V5-DEST- ΔN-Tcf4 plasmid 
pAd/CMV/V5-DEST- ΔN-Tcf4 band3 
V5 pAd/CMV/V5-DEST- ΔN-Tcf4 band2 
V6 pAd/CMV/V5-DEST- ΔN-Tcf4 band1 
V7 pAd/CMV/V5-DEST-Tcf4wt plasmid 
λM Figure 5.12.4.1 Lambda 3 marker 
 
The control PCR showed no bands for all 3 bands samples but clear bands 
at the controls.  
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3.4 Biological activity of the pAd/CMV/V5-DEST-ΔN-Tcf4 
virus 
12x6cm Pds with 7x105 HT29 cells and LT97 cells were plated and after 2 
days they were infected with a 10x multiplicity of infection with 
pAd/CMV/V5-DEST- ΔN-Tcf4 band3 and the control virus Cox AS 
virus. The RNA was extracted and analyzed according to 5.3 - 5.6. 
Sybr® green I Real Time PCR was used to quantify survivin in the HT29 
and LT97 samples. Taqman® probe kits were used to detect Tcf4, FGF18 
and IGFBP3 in both cell lines. 
 
pAd/CMV/V5-DEST- ΔN-Tcf4 infection caused a clear up-regulation of 
Tcf4 in both cell lines (see figure 3.4.1). In HT29 cells the virus infection 
caused that the RNA levels of Tcf4 were up-regulated to 168 ± 24.21% (p 
= 0.0048). Furthermore RNA levels of Tcf4 virus infected LT97 cells 
increased to 470 ± 192.4% (p = 0.0048). In fact both cell lines expressed 
stronger Tcf4 if they were infected with the pAd/CMV/V5-DEST- ΔN-
Tcf4 virus. 
 
In HT29 cells the virus did not cause a down-regulation of survivin RNA 
levels but this may be due to the high standard deviation of GAPDH 
results. The adenovirus had no effect on survivin RNA levels in LT97 
cells. The virus also did not impact on FGF18 levels. 
IFGBP3 could not be detected in HT29 cells because of too low RNA 
levels. In LT97 cells the IGBP3 RNA level was elevated (156% of the 
control level) but this was not statistically significant. 
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Figure 3.4.1: % in comparison with the control in pAd/CMV/V5-
DEST- ΔN-Tcf4 infected HT29 and LT97 cells  
(Tcf4) 
The value of 100 indicates the same value as the control. 
* indicates statistically significant data 
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Figure 3.4.2: % in comparison with the control in pAd/CMV/V5-
DEST- ΔN-Tcf4 infected HT29 and LT97 samples  
(Survivin, FGF18, IGFBP3) 
The value of 100 indicates the same value as the control. 
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4. Discussion 
4.1 Cell biological effects of sulindac 
Sulindac has been introduced as a drug that targets wnt-signalling to 
induce apoptosis in chemoprevention treatment of high-risk colorectal 
cancer patients (Piazza et al. 2009). To investigate the underlying cellular 
mechanisms we have analysed the drug’s impact on gene expression in 
colonic cells. This analysis focused on survivin and FGF18 because they 
are wnt-target genes (Altieri 2008, Sonvilla et al. 2008) and on IGFBP3 
whose regulation in colorectal tumor cells is not yet understood.  
 
On the RNA level survivin was down-regulated in both HT29 carcinoma 
and LT97 adenoma cells. In the carcinoma cell line the inter-experimental 
variation and consequently the standard deviation for the controls was 
rather high but it stays statistically significant. In LT97 cells the impact of 
sulindac was less but it was a statistically significant down-regulation. 
This effect was quite robust with low standard deviations in both the 
control and the survivin group (sulindac treated samples: 3.6% of the 
control; control samples: 18% of the control). On the protein level 
sulindac also caused a decrease in both cell lines. Moreover, the impact on 
survivin protein levels was much stronger in LT97 cells than in HT29 
cells. 
 
Survivin is an anti-apoptotic protein that inhibits caspase activity (Altieri 
2010). Down-regulation of such a protein therefore constitutes a pro-
apoptotic effect that can be employed for therapeutic purposes (Lladser et 
al. 2011). The pro-apoptotic effect can explain the concentration-
dependent cell loss that had previously been described for sulindac 
(Piazza et al. 2009). 
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FGF18 also is a wnt-target gene, but surprisingly sulindac treatment did 
not impact on the FGF18 RNA levels in HT29. This effect was only seen 
in LT97 whose FGF18 RNA levels decreased to 66% of the control by 
10µM sulindac but the standard deviation of the control was too high 
(47.8%) to permit a statistically significant difference. For this reason 
FGF protein secreted into the medium was not determined. 
 
FGF18 is a strong survival factor in colorectal cancer cells that is 
progressively up-regulated in a wnt-dependent fashion. It is therefore a 
target of therapy whose down-regulation also constitutes a pro-apoptotic 
effect. The lack of effect in our experiments may be due to the 
comparatively low wnt-signalling activity in the cell lines we used that 
does not allow further inhibition (Sonvilla et al. 2008). 
 
For IGFBP3 no connection with wnt-signalling has previously been 
preported and the results of your own experiments also do not solidly 
support a wnt-dependent modulation. The analysis of IGFBP3 RNA levels 
demonstrated a slight increase in HT29 cells but the intra-experimental 
variations and consequently the standard deviations were large. In LT97 
cells sulindac treatment had little influence on the IGFBP3 level. 
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4.2 Production and biological activity of adenoviral Tcf4-
blocking vector 
As chemical compounds are never completely specific, a specific genetic 
construct is needed to establish the role of any cellular target for therapy. 
We plan to use a dominant-negative Tcf4-mutant, because it blocks wnt-
dependent signalling down-stream of APC whose mutation in colorectal 
cancer cells causes a constitutive activation of the pathway (Kinzler and 
Vogelstein 1996). As activation of wnt-signaling activates growth as well 
as survival signaling (Giles et al. 2003) pathway blockade is expected to 
result in strong inhibition of growth and survival. Therefore it was 
decided to produce a vector for strong transient over-expression of a 
dominant-negative Tcf4-mutant. 
As the transfection rate by lipofection is low for HT29 (15.87% 
fluorescent cells, see table 3.2.1) and extremely low (1-2%; data not 
shown) for LT97 it was necessary to produce a viral vector for efficient 
transient expression. The choice to produce an adenoviral vector was 
based on the fact that several other adenoviral constructs have previously 
been used in the laboratory including several control viruses (Allerstorfer 
et al. 2007; Sonvilla et al. 2008). 
 
So the ΔN-Tcf4, VP16- ΔN-Tcf4 and Tcf4wt cassettes were excised with 
BamHI and XhoI from the pAAV-IRES-hrGFP-inserts vectors 
(Holnthoner et al. 2002) and cloned into a pENTR-1A vector by ligation 
reaction. Subsequently, the pENTR-1A-inserts are recombined into the 
adenoviral expression vector pAd/CMV/V5-DEST™ vector by gateway 
cloning reaction. Only the pAd/CMV/V5-DEST- ΔN-Tcf4 virus was 
propagated in HEK293 cells and isolated by ultracentrifugation which 
gives rise to 3 bands. Only the lowest band which is called band 3 had a 
high virus titer of 15800000/µl infectious units. 
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Infection of HT29 and LT97 cells with 10x moi of the virus resulted in 
clear statistically significant up-regulation of Tcf4 RNA levels in both 
virus infected cell lines. In LT97 cells the increase of the RNA level was 
higher (470%) than in HT29 cells (168%). An explanation could be that 
the Tcf4 levels of controls in LT97 (CT = 28.11) cells were lower than 
those in HT29 cells (CT = 26.63). 
However, pAd/CMV/V5-DEST- ΔN-Tcf4 infection did not impact 
statistically significantly on the RNA levels of survivin, FGF18 and 
IGFBP3. 
Further experiments will be necessary using different multiplicity of 
infection in order to explore the abilities of the virus inhibiting the wnt 
pathway. 
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5. Materials and methods 
5.1 Cell lines and cell culture 
5.1.1 Cell lines: 
LT97 is a colorectal adenoma cell line which is very close to primary 
adenoma cells. It has lost both alleles of APC, one allele of Ki-RAS is 
mutated but p53 is still functioning (Richter et al. 2002). The cells have a 
60% CD44+ subpopulation (Schulenburg et al. 2007). HT29 is a 
colorectal carcinoma cell line which consists exclusively of CD44+ cells 
and was obtained from the American Type Culture Collection. 
5.1.2 Cell culture materials and methods for HT29 cultivation 
5.1.2.1 List of materials 
Cell culture dishes: Petri dishes (PD) with 10 cm and 6 cm diameter 
PBS/EDTA: 2x 1l powder flasks Dulbecco`s Phosphate Buffered Saline 
(Sigma) is dissolved in 1500ml aqua bidest; 7.44g EDTA is dissolved in 
200ml aqua bidest and adjusted to pH=7.5; both solution are mixed, filled 
up to 2l and autoclaved; 
Trypsin/EDTA in PBS: 45 ml PBS with 5ml Trypsin/EDTA 
HT 29 cultivation medium: 10% FCS, 450 ml MEM with 50ml FCS and 
2ml Penstrep 
5.1.2.2 Splitting of cells 
Medium is removed. The cells are washed with 5ml PBS/EDTA if 10 cm 
PDs are used. Subsequently, 500µl till 800µl Trypsin/EDTA are added 
and the PD is incubated at 37°C for about 5 minutes till the cells are 
completely detached. This reaction is stopped with 10 ml HT29 
cultivation medium. The cells can be separated by pipetting up and down 
and split according to needs of the experiments. In order to count the cell 
number counting chambers are used. 
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5.1.3 Cell culture materials and methods for LT97 cultivation 
5.1.3.1 List of materials 
Cell culture dishes: Petri dishes (PD) with 10 cm and 6 cm diameter 
PBS/EDTA 
Basic medium 10l (400 ml aliquoted): ph 7.0, 2500ml Leibovitz 
Medium, 100 ml L-Glutamin, filled up to 10l with Aqua bidest, 1 bottle  
Ham`s F12 Medium (Sigma Nr. N6760), 11.8g NaHCO3, 0.44g 
CaCl2x2H2O, sterile filtrated, aliquoted, 250ml HEPES buffer 
LT full medium: 400ml Basic medium are added, 8ml FCS, 0.8ml 
Insulin, 1.6ml Penstrep, 1.6ml V10, 400µl EGF (30µg/ml), 800µl 
Gentamycin (500x) 
5.1.3.2 Splitting of cells 
Medium is removed. The cells are washed gently twice with 1ml 
PBS/EDTA. This is done very gently because the cells detach easily. The 
cells are detached with 750-1000µl PBS/EDTA and incubated at 37°C for 
about 10-15 minutes. During that time the PDs are knocked several times 
in order to detach the cells more efficiently. Then the cells are suspended 
in twice 5 ml LT full medium, transferred into a falcon tube and 
centrifuged at 1100rpm for 5 minutes. Supernatant is removed and the cell 
pellets are dissolved in 4 ml LT full medium. The cells can be split 
according to the experiment. 
5.2 Sulindac treatment 
5.2.1 List of materials 
HT29 sulindac treatment media: MEM with 2ml Penstrep but serum 
free, 1:1000 sulindac (stored at -20°C, 10mM stock), 1:100 1% BSA 
HT29 treatment control media: HT29 sulindac treatment media without 
sulindac 
LT97 sulindac treatment media: LT full medium without FCS and 
Insulin, 1:1000 sulindac (stored at -20°C, 10mM stock), 1:100 1% BSA 
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LT97 treatment control media: LT97 sulindac treatment media without 
sulindac 
5.2.2 Procedures of sulindac treatment for HT29 cells 
HT29 cells are split in order to have 5x105 cells in each 6cm Pd. The cells 
are cultivated for 2 days before changing the medium to HT29 sulindac 
treatment or HT29 treatment control medium. On day 3 the cells are ready 
for further analysis. 
5.2.3 Procedures of sulindac treatment for LT97 cells: 
LT97 cells are split at a ratio of 1:3 and grow till 50-65% confluence. 
Subsequently, the medium is changed to LT97 sulindac treatment or 
control medium. On the next day the cells are ready for further analysis. 
In order to detect IGFBP3 with Western Blot: LT97 cells are incubated 
with 3ml LT97 sulindac treatment medium or 3ml LT97 treatment control 
medium in Pds with 6cm diamter for 2 days. 
5.3. RNA isolation 
5.3.1 List of materials 
0.1M NaOH 
DEPC water 
70% EtOH in DEPC water 
PeqGold Trifast™ (Peqlab Biotechnologie, Erlangen, Germany) 
Chloroform 
Isopropanol 
5.3.2 Procedures of RNA isolation 
Scrapers have to be treated 10 minutes with 0.1 NaOH and 10 minutes 
with 70% EtOH and then dried in the sterile work bench to make them 
RNAse-free. The medium is removed from the cells, 1000µl PeqGold 
Trifast™ is added and the cultures incubated 5 minutes on ice. 
Subsequently, the cells are scraped off and homogenized by a syringe and 
a 0.6-in-diamter needle and transferred to Eppendorf tubes. 200µl 
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chloroform is added; the tubes are vortexed for 30 seconds and then left 
on ice for 10 minutes. After that the tubes are centrifuged at 15000rpm at 
5°C for 15 minutes to achieve phase-separation. The upper phase which 
contains the RNA is pipetted into new Eppendorf tubes. 500µl 
isopropanol is added and the samples are vortexed for 30sec and 
incubated on ice for 10 minutes to precipitate of the RNA. Subsequently, 
the Eppendorf tubes are centrifuged at 12200rpm at 4°C for 10 minutes. 
Supernatant is removed carefully and the RNA pellet is washed with 70% 
EtOH and centrifuged at 15000rpm at 4°C for 15 minutes. The 
supernatant is removed carefully and the pellet is dried in the sterile work 
bench. After that it is dissolved in 15 till 50µl DEPC water dependent on 
the size of the pellet. It is denatured at 65-70°C for 10 minutes. The RNA 
solution is stored at -80°C. 
5.4 RNA measurement 
The RNA amount is measured with NanoDrop™ PEQLAB 
spectrophotometer (Peqlab Biotechnologie, Erlangen, Germany) and the 
ND1000 sofware. 1µl RNA sample are used to quantify the concentration 
in ng/µl. λ 269/280 ratio 
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5.5 cDNA synthesis 
5.5.1 List of materials 
DEPC water 
Random Hexamer Primer Mix (1mM stock, used 1:10 diluted; GE 
Healthcare, Piscataway, NJ, USA) 
dNTP Mix 
RNase Inhibitor: Riboblock RI 
5xfirst strand buffer (MMuLVRT-buffer, Fermentas, Burlington, 
Canada) 
RevertAid™ MMuLV reverse transcriptase (Fermentas, Burlington, 
Canada) 
 
5.5.2 Procedures of cDNA synthesis 
 
Table 5.5.2.1: Random Hexamer Primer Master Mix (per sample) 
Volume Substance 
1µL 100 µM random hexamer primer mix  
1.5µL DEPC-water 
 
 
Table 5.5.2.2: Mastermix for cDNA synthesis (per sample) 
Volume Substance 
4 µl 5x first strand buffer 
2µl dNTP Mix 
0.5µl Riboblock RI 
 
The goal of cDNA synthesis is the production of single stranded cDNA by 
reverse transcription. The advantage to use random hexamer primers is 
that all RNAs can be converted into cDNA. 
All preparations are done on ice. 2µg RNA is pipetted into PCR tube and 
diluted to final volume of 10µl with DEPC water. 2.5µl Random Hexamer 
Primer Mastermix is added per sample. The mix is then heated to 70°C for 
5 minutes and returned to ice again. 6.5µl Mastermix is added per sample 
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and the PCR tubes are heated to 25°C for 5 minutes. After that 1µl reverse 
transcriptase is added. Subsequently, the PCR tubes are incubated at 25°C 
for 10 minutes, then at 42°C for 60 minutes (DNA elongation) and finally 
the reaction is stopped at 70°C for 10 minutes. After that the samples are 
kept on ice and 80µl DEPC water is added. The samples are vortexed and 
can be stored at -20°C.  
5.6 Real Time PCR 
The polymerase chain reaction (PCR) is a method to amplify and detect a 
gene of interest using a DNA template. PCR is characterized by 
reiterating cycles of denaturation, annealing and extension steps. Forward 
and reverse primers which are oligonucleotides bind specifically at the 
annealing step and subsequently the polymerase synthesizes subsequently 
the complementary strand in the extension phase. 
Real Time PCR can be used to quantify the amount of a specific cDNA in 
a sample during the exponential stages of PCR. 
In our experiments 2 different methods of Real time PCR were used: 
Syber® Green I PCR and Taqman® PCR. 
5.6.1 Sybr® Green I PCR: 
5.6.1.1 Explanation of Sybr® Green I PCR 
Sybr® Green I PCR is characterized by using the Sybr® Green I 
fluorescent dye which binds preferentially double stranded DNA. If the 
DNA is amplified by PCR the Sybr® Green I dye binds to the DNA and 
fluorescence light is emitted. The more DNA is produced the stronger is 
the fluorescence signal and this can be used to quantify the cDNA 
template in the exponential stages of PCR. 
The Sybr® Green I dye also stains unspecific side-products of the 
amplification (results of unspecific priming, primer dimers) and thus a 
melting temperature curve is used to prove the specificity of the PCR 
product after amplification. 
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5.6.1.2 Procedures of Sybr® Green I PCR 
Table 5.6.1.2.1: cDNA mix 
Volume/tube Substance 
1µl-9µl cDNA sample 
8µl-0µl DEPC water 
9µl Total 
 
Table 5.6.1.2.2: Sbr® Green I PCR Mix 
Volume/tube Substance 
1µl Primers 
10µl Taqman® Universal PCR Masermix (Applied Biosystems, Foster 
City, CA, USA) + 1:50 Sybr® Green I dye 
11µl Total 
 
11µl of the Sbr® Green I PCR Mix (look at table 5.6.1.2.2) and 9µl of the 
cDNA mix (look at table 5.6.1.2.1) are pipetted into each well of a 96-
well-plate (MicroAmp) which is suitable for Real Time PCR. After 
pipetting the 96-well-plate has to be covered with an adhesive tape and 
centrifuged with 1100rpm at room temperature for 5 minutes. The Real 
time PCR is run in the ABI 7000 thermocycler  and analyzed with ABI 
PRISM 7000 SDS software (Applied Biosystems, Foster City, CA, USA).  
The Real time PCR is separated in 2 steps: 1repeat at 95°C for 10 minutes 
and 40 repeats at 95°C for 0:15 minutes and at 60°C for 1 minute. 
Additionally, after the Sybr® Green I PCR a melting temperature curve 
analysis has to be performed in order to test the specificity of the PCR 
product. 
5.6.2 Taqman® PCR 
5.6.2.1 Explanation of Taqman® PCR 
Taqman® PCR is characterized by the use of specific Taqman® probes 
which binds within the gene of interest amplicon. Taqman® probes are 
labelled with a fluorescent dye and a quencher on each side of the probe 
(look at figure 5.6.2.1.1). If the fluorescent dye is in the vicinity of the 
quencher no the fluorescence signal can not be detected. The exonuclease 
activity of the DNA polymerase causes the degradation of the Taqman® 
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probes which leads to dequenching so that the fluorescence signal can be 
detected. The more Taqman® probes are degraded the stronger is the 
fluorescence signal and this fact can be used to quantify the specific 
cDNA relatively in the exponential stages of PCR. 
Taqman® PCR is more specific and more sensitive than Sybr Green I 
PCR due to the specific Taqman® probes. 
 
Figure 5.6.2.1.1: Principle of Taqman® probes 
http://upload.wikimedia.org/wikipedia/en/0/07/Taqman.png 
 
 
5.6.2.2 Procedures of Taqman® PCR 
Table 5.6.2.2.1: Taqman® PCR Mix 
Volum/tube Substance 
1µl Specific Taqman® probes and primers 
10µl Taqman® Universal PCR Masermix (Applied Biosystems, Foster 
City, CA, USA) 
11µl Total 
 
The same procedures are done as in 5.6.1.2. The Taqman® PCR Mix 
(look at table 5.6.2.2.1) is used and no melting temperature curve analysis 
is necessary after PCR run. 
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5.7 Protein isolation 
5.7.1 List of materials:  
1xPBS 
Acetone 
Complete Stock solution: 1 tablet Complete (Roche) dissolved in 2ml 
aqua bidest 
Table 5.7.1.1 Hepes buffer 
Amount Substance 
1ml 1M Hepes (PAA 
3ml 1M NaCl 
2ml Glycerol 
40µl 0.5M EDTA 
200µl 1M NaF solution 
100µl 1M NaVO4 solution 
200µl Triton X 
30µl 1M MgCl2 solution 
2 tablets Complete 
13.43ml Aqua bidest 
 
5.7.1 Procedures of protein isolation: 
Pds are washed with cold 1xPBS. Then 100-200µl Hepes buffer are added 
and the Pds are incubated for a few minutes on ice. The cells are scraped 
off and homogenized by a syringe and a 0.6-in-diamter needle and 
transferred in Eppendorf tubes. The samples are kept on ice for about half 
an hour and they are vortexed three times. Subsequently, the Eppendorf 
tubes are treated in an ultrasound bath for about 13 minutes. After that 
they are centrifuged at 15000rpm at 4°C for 5 minutes to remove debris. 
Then the supernatant is transferred in new Eppendorf tubes and is stored 
at -20°C. 
 
In order to isolate protein samples for IGFBP3 detection the proteins are 
precipitated with acetone: The medium is transferred into falcon tubes and 
complete stock solution is added 20µl complete stock solution is added 
per 1ml medium. 100µl or 200µl aliquots are transferred into Eppendorf 
tubes and the tenfold amount of acetone is added. The mixture is 
110 
incubated on ice for 30 minutes. After that the vials are centrifuged at 4°C 
at 15000rpm for 30 minutes. The supernatant is discarded gently and the 
Eppendorf tubes are dried in the lamina flow. Subsequently, 10µl aqua 
bidest and 10µl 2x sample buffer (see 5.9.1) are added and the samples 
are stored at -20°C. Protein measurement is not possible under these 
conditions. 
Alternatively, the 3ml medium are transferred into a 15ml falcon tube and 
complete stock solution 20µl per 1ml medium is added. After that 
isopropanol is added at the ratio 2:1 and the sample is incubated at -20°C 
overnight. Next day the samples are thawed on ice and centrifuged at 
3700rpm at 4°C for 45 minutes. The supernatant is discarded. The pellet is 
dried in the lamina flow and 10µl aqua bidest and 10µl 2xsample buffer is 
added (see 5.9.1). 
5.8 Protein measurement 
5.8.1 List of materials: 
Coomassie`s Protein Assay Dye Reagent (Bio-Rad Laboratories, 
Hercules, CA, USA): 1:5 diluted with Aqua bidest, 150µl of the dilution 
per sample 
Hepes buffer 
BSA solution (1µg/µl) 
5.8.2 Procedures of protein measurement 
1µl protein sample is mixed with 9µl Aqua bidest. The protein 
concentration is determined in duplicates. Protein concentration is 
calculated from a BSA standard curve determined with each assay. 
Firstly, all substances are mixed according to table 5.8.2.1 and as the last 
ingredient 150µl Coomassie`s Protein Assay Dye Reagent dilution is 
added. The optical density of the samples is measured at 590nm. The 
standard curve is determined from the absorbance of tubes containing 0-
7µg BSA. 
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Table 5.8.2.1 Pipetting scheme for the BSA standard curve 
BSA conc (1µg/µl) 0 1 2 3 4 5 6 7 8 9 
µl Aqua bidest 9 8 7 6 5 4 3 2 1 0 
µl Hepes buffer 1 1 1 1 1 1 1 1 1 1 
µl BSA (1µg/µl) 0 1 2 3 4 5 6 7 8 9 
Total volume in µl 10 10 10 10 10 10 10 10 10 10 
 
5.9 SDS Polyacrylamid Gelelectrophoresis 
5.9.1 List of materials: 
Table 5.9.1.1: 2x sample buffer 
Amount Substance 
4% SDS 
20% Glycerol 
10% 2-Mercaptoethanol 
0.125M ph 6.8 Tris/HCl 
traces Bromphenol blue 
 
 
Table 5.9.1.2: 10x Electrophoresis buffer (1:10 is used) 
Amount Substance 
72g (14.4%) Glycin 
15g (3%) Tris 
5g (1%) SDS 
500ml Aqua bidest 
 
10% APS: 0.1g/ml 
protein marker (PageRuler™ Prestained Protein Ladder, Fermentas, 
Burlington, Canada) 
40% Acrylamid 
10% SDS 
TEMED 
1.5 Tris ph 8.8 
1 Tris ph 6.8 
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5.9.2 Procedures of SDS Polyacrylamid Electrophoresis 
 
Table 5.9.2.1: Separation gel containing 10% acrylamid (1 gel) 
Volume Substance 
1.25ml 40% Acrylamd 
1.25ml 1.5M Tris, ph 8.8 
2.45ml Aqua bidest 
0.05ml 10% SDS 
0.025ml 10% APS 
0.0025ml TEMED 
 
Table 5.9.2.2 Stacking gel containing 4% acrylamid (1 gel) 
Volume Substance 
0.25ml 40% Acrylamd 
0.313ml 1M Tris, ph 6.8 
1.9ml Aqua bidest 
25µl 10% SDS 
12.5µl 10% APS 
2.5µl TEMED 
 
SDS-PAGE separates the proteins according to their molecular weight. 
The polyacrylamid gel is composed of two sections: The stacking gel and 
the separation gel. First of all the separation gel reaction mixture (see 
table 5.9.2.1) is poured into a sandwich of two glass plates with a spacer 
of 1mm. In order to have a plane upper edge for the separation gel 70% 
ethanol are added on the top of the polymerisation mix and removed 
carefully after the gel has solidified. Subsequently the stacking gel (look 
at table 5.9.2.2) is poured on top of the separation gel and a comb for the 
slots is applied. The stacking gel solidifies in about 60 minutes. The comb 
is removed and the gel is put into the electrophoresis apparatus which is 
filled with 1x electrophoresis buffer (table 5.9.1.2). 50µg proteins sample 
is mixed with 2x sample buffer (look at table 5.9.1.1) or 4x sample buffer 
and the mixture is heated at 70°C for 1 minute. Subsequently, the samples 
(up to 30µl) and 5µl protein marker (PageRuler™ Prestained Protein 
Ladder, Fermentas, Burlington, Canada) are loaded into the slots. The gel 
is run at 60V for 15 minutes and at 125V for 1 hour and 15 minutes. 
 
113 
5.10 Western Blot and immunological detection of proteins 
5.10.1 List of materials for Western Blot 
Table 5.10.1.1 10x Blotting buffer 
Amount Substance 
72g (14,4%) Glycin 
15g (3%) Tris 
1g (0.2%) SDS 
Filled up to 500ml 
with 
Aqua bidest 
 
Table 5.10.1.2 1x Blotting buffer 
Amount Substance 
50ml (10Vol%) 10x Blotting buffer 
100ml (20Vol%) Methanol 
350ml (70Vol%) Aqua bidest 
 
Methanol 
Ponceau S staining solution (Sigma, St. Louis, MO, USA) 
Wash buffer: 1x PBS + 0.1% Tween 20 (Sigma Ultra) 
 
5.10.2 Procedures of Western Blot 
The goal of Western Blot is to transfer the separated proteins from the 
polyacrylamid gel onto a BioTrace™ PVDF membrane (Pall Corporation, 
East Hills, NY, USA). During the transfer the proteins move towards the 
positive pole. 
 
The Western Blot Sandwich is built as shown in figure 5.10.2.1: pointing 
toward the negative pole of the blotting chamber a sponge and 3 filter 
papers which are soaked with 1x blotting buffer (look at table 5.10.1.2) 
are positioned. The gel is put on top and is then covered with the BioTrace 
PVDF membrane which is activated by methanol. The blotting sandwich 
is completed with 3 more filter papers and another sponge. The Western 
Blot is transferred in 1x blotting buffer and it is run at 25V overnight in 
the cold. Next day the Western Blot Sandwich is disassembled and the 
membrane is washed in aqua bidest. After that the membrane is stained 
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with Ponceau S staining solution in order to assess the success of the 
blotting. Subsequently, the membrane is de-stained with wash buffer and 
it can be dried after treatment with methanol. 
 
Figure 5.10.2.1: Western Blot Sandwich 
http://www.bme.gatech.edu/vcl/WesternBlotting/Background/Assets/nitromembraneSandwich.gif 
 
 
5.11 Immunological detection of proteins 
5.11.1 List of materials for immunological detection of proteins 
Wash buffer: 1x PBS + 0.1% Tween 20 (Sigma Ultra) 
Blocking solution: 20ml Wash buffer + 1% Skim milk powder (0.2g) 
Table 5.10.3.1: List of primary antibodies 
Target Specificity Dilution Company Protein size 
Survivin rabbit 1:1000 abcam 16.5 kDA 
IGFBP3 rabbit 1:1000 Sigma 40 kDA 
β-Actin mouse  1:1000 Sigma 42 kDa 
 
Table 5.10.3.2: List of secondary antibodies 
Target Specificity Dilution Company Label 
Rabbit IgG goat 1:20000 Bethyl HRP 
Mouse IgG goat 1:10000 PIERCE HRP 
 
5.11.2 Procedures for immunological detection of proteins 
The dried BioTrace PVDF membrane is reactivated with methanol. After 
that the membrane is blocked with blocking solution for about half an 
hour. Subsequently, the membrane is incubated with the primary antibody 
solution on a shaker at 4°C overnight. The primary antibody binds 
specifically to the protein of interest. Next day the membrane is washed 
with wash buffer 3 times for 10 minutes. After that the membrane is 
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incubated with the secondary antibody solution for about 1 hour. The 
secondary antibody binds specifically the primary antibody and is labelled 
with a horseradish peroxidise (HRP). Subsequently the membrane is 
washed with wash buffer 3 times for 10 minutes and the secondary 
antibody is detected with a detection reagent (Amersham™ ECL Plus or 
Prime Western Blotting Detection System, GE Healthcare). The 
membrane is incubated with the detection reagent for 5 minutes. HRP 
produces luminol from the detection reagent and causes 
chemiluminescence which can be detected by x-ray film. The strength of 
the resulting bands is proportional to the amount of protein on the 
membrane. β-Actin is used for the standardization of the measured 
proteins. 
5.11.3 Quantitative Analysis with ImageQuant 5.0 
The X-ray films are scanned and the bands are analyzed by 
ImageQuant5.0. 
5.12 Plasmid Amplification 
5.12.1 Production of competent TOP10 E.coli 
5.12.1.1 List of materials for SEM competent TOP10 E.coli 
Table 5.12.1.1.1 300 ml 10x TB-buffer (autoclaved) 
Amount Substance 
100mM (3.0237g/100ml) Pipes, Sigma P1851 
150mM (2.2053g/100ml) CaCl2*2H2O 
2.5M (18.6375g/100ml) KCl 
Adjusted to ph 6.7 With KOH 
 
550mM MnCl2-solution: (5.44 MnCl2-tetrahydrat/50ml), sterile filtrated, 
stored at 4°C in the dark 
1x SEM TB-buffer: 320ml autoclaved aqua bidest + 40ml 10x SEM TB-
buffer + 40ml 550mM MnCl2; stored in 30ml portions at -20°C 
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5.12.1.2 Production of SEM competent TOP10 E.coli  
1 colony of a streak is incubated in 7ml LB medium at 200rpm at 37°C for 
5 hours on the shaker. Subsequently 10-50µl of the culture are pipetted in 
2x200ml LB in large flasks and they are incubated at 200rpm at room 
temperature overnight till the bacteria density is at OD600= 0.3-0.6. After 
that the cultures are stored on ice. Then the TOP10 solution is filled into 
8x 50ml falcon tubes and incubated on ice for 10 minutes. Then they are 
centrifuged at 2500g at 4°C for 15 minutes and the supernatant is 
discarded. The 8 pellets are resuspended carefully in 40ml cold 1x SEM 
TB-buffer and then transferred into 2 falcon tubes that are then vortexed 
at 1000rpm 3 times for 15 seconds and kept on ice between. 
Subsequently, they are incubated on ice for 10 minutes. After that they are 
centrifuged at 2500g at 4°C for 10 minutes and the supernatant is 
discarded. Both pellets are diluted in 10ml 1x SEM TB-buffer with the 
same procedure above and then they are transferred in 1 falcon tube. 
DMSO is added and mixed till an end concentration of 7Vol% 
(0.7ml/10ml). The falcon tube is incubated on ice for 10 minutes. The 
competent TOP10 solution is filled in 700µl portions in 1.5 Eppendorf 
tubes and they are frozen in liquid N2 and then they are stored at -80°C. 
5.12.1.3 List of materials for Chinese Hyper-Competent Cells (Tu et 
al. 2005) 
Chinese SOB medium (liquid): per liter  
20g Tryptone (bacto), 5g yeast extract, 10mM NaCl (584mg);  
Autoclaving 
Chinese SOC medium: 
Cool Chinese SOB medium  
Addition of: 
 2.5 mM MgCl2 (2.5ml of  1M stock 9.5g/100ml),10mM MgSO4 ( 10ml of 
1M MgSO4 stock solution 12,04g/100ml), 20mM glucose (10ml of 2M 
glucose stock solution 36g/100ml); 
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Solid SOC antibiotics plates: 
15g Select Agar (Sigma) per 1l Chinese SOB medium; addition: as the 
production of Chinese SOC medium + antibiotics 
 
Chinese 10* TB buffer:  
equal to the normal SEM TB buffer with the adaption: 750 mM 
CaCl2*2H2O (11,0265g/100ml) 
5.12.1.4 Production of Chinese Hyper-competent cells 
10µl or 100µl TOP10 glycerol stock is thawed at room temperature. 40 ml 
liquid Chinese SOC medium is added. The TOP10 culture is incubated at 
37°C for 1 hour. Subsequently, the TOP10 culture is shaken at 200rpm at 
37°C for 2-3 hours till OD600 of 0.2-0.4. Then the cells are centrifuged at 
8000rpm at 4°C for 2 minutes and the supernatant is discarded 
(centrifuge: Sorvall RC-5B; rotor: F215-8x50).  The cells are resuspended 
in 20ml autoclaved, cold 1xTB (including 75mM CaCl2) and incubated 
on ice for 25 minutes. Subsequently, the solution is centrifuged at 
8000rpm at 4°C for 2 minutes and the supernatant is discarded. 4ml 
autoclaved, cold 1xTB is mixed with absolute glycerol to a final 20 vol% 
and the pellet is resuspended with that and stored at -80°C. 
5.12.2 Transformation, plating and inocoluation 
5.12.2.1 List of materials 
Liquid LB: 20g LB Broth (Sigma L3022-1KG) in 1l aqua bidest, 
autoclaved, 100µg/ml ampicillin 
LB/agar plates: 15g Select Agar (Sigma A5054-250G) in 1L LB, 
autoclaved, 100µg/ml ampicillin; plates are poured over 60°C; 
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Table 5.12.2.1.1 SEM SOB-medium (per liter) 
Amount Substance 
20g  Trypton 
5g  Yeast extract 
0.5g NaCl 
10ml  250mM KCl (1.86g KCl/100ml H2O) 
Adjusted to ph 7 With NaOH 
 
 
Table 5.12.2.1.2 SEM SOC-medium 
Amount Substance 
Variable  SOB medium 
1/100 Vol Autoclaved 1M MgCl2-solution (9.5g Mg/100ml) 
1/100 Vol Autoclaved 2M glucose-solution (36g/100ml) 
 
For Chinese SOC medium and Chinese SOC antibiotics plates look at 
5.12.2.1. 
5.12.2.2 Procedures of transformation, platting and inoculation 
SEM competent TOP10 E.coli: 
SEM competent TOP10 E.coli are thawed on ice. 1µl plasmid is 
transferred in 1.5ml Eppendorf tubes and kept on ice. 200µl competent 
TOP10 cells are added and mixed gently. They are incubated on ice for 20 
minutes. Subsequently, the samples are heat shocked in a water bath at 
42°C for 35 seconds. 800µl SOC-medium is immediately added after the 
water bath and the samples are inverted twice. Then they are transferred 
into 14ml tubes and shaken at 200rpm at 37°C for 1 hour. 1/50 of the 
samples are plated on LB/agar plates with antibiotics. The remaining of 
sample solution is transferred in 1.5ml Eppendorf tubes and centrifuged at 
1000g at room temperature for 3min. Subsequently, most of the 
supernatant is discarded. This step is used to decrease the volume. The 
pellet is diluted with the rest of the medium and plated on LB/agar plates 
with antibiotics. After that the plates are incubated upside down at 37°C 
overnight. Next day colonies are picked with autoclaved toothpicks and 
are transferred in 14ml tubes which are filled with 6ml liquid LB with 
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antibiotics and then they are shaken at 200 rpm at 37°C overnight. Next 
day the DNA is isolated by miniprep. Aliquots of the bacteria culture can 
be stored at -80°C if it is 1:1 mixed with 40% glycerol. 
Commercial  competent TOP10 E.coli:  
1µl plasmid is transferred in 1.5ml Eppendorf tubes and kept on ice. 20µl 
competent TOP10 E.coli cells (invitrogen) are added and mixed gently. 
They are incubated on ice for 30 minutes. Subsequently, the samples are 
heat shocked in a water bath at 42°C for 30 seconds and immediately put 
on ice thereafter. 250µl SOC-medium is added and mixed with the 
sample. Then the 1.5ml Eppendorf tubes are incubated on the shaker at 
900 rpm at 37°C for 1 hour. 1/50 of the samples are plated on LB/agar 
plates with antibiotics. The rest of the samples are plated on another plate. 
After that the plates are incubated upside down at 37°C overnight. The 
next steps are equal with the SEM competent TOP10 E.coli. 
Chinese Hyper-competent TOP10 E.coli: 
Solid SOC antibiotics plates are pre-heated at 37°C for 1 hour. 100µl 
Chinese hyper-competent cells are mixed with 1ng plasmid DNA and 1µl 
DMSO. Transformation mix is incubated on ice for 30 minutes. 
Subsequently, the transformation mix is heat-shocked at 42°C for 90 
seconds and then it is incubated on ice for 2 minutes. 400µl liquid Chinese 
SOC is added and the sample is shaken at 200rpm at 37°C for 45 minutes. 
The sample is spread on the pre-heated plates and they are incubated at 
37°C overnight. The next steps are equal with the SEM competent TOP10 
E.coli. 
 
5.12.3 Miniprep 
Miniprep with column: 
Wizard® Plus SV Minipreps DNA Purification System (Promega) is used 
for isolation of the plasmid from the TOP10 bacteria which have grown 
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overnight. 1ml of bacterial culture is transferred into 1.5 ml Eppendorf 
tubes. They are centrifuged at 10000g for 2 minutes and the supernatant is 
discarded. This procedure is repeated three times. The final pellet is 
resuspended completely in 250ml Cell Resuspension Solution. Then 
250µl Cell Lysis Solution is added, mixed by inverting and incubated 3 
minutes. Subsequently, 10µl Alkaline Protease Solution is added and 
incubated for 5 minutes. Then 350µl Neutralization Solution is added and 
mixed completely by invertion. The samples are centrifuged at 14000g for 
10 minutes. The Spin Column is inserted into the Collection Tube and the 
supernatant is transferred. Subsequently, it is centrifuged at 14000g for 1 
minute. The flowthrough is discarded, 750µl Column Wash Solution is 
added to the Spin Column and the samples are centrifuged at 14000g for 1 
minute. Again the flowthrough is discarded, 250µl Column Wash 
Solution is added and it is centrifuged at 14000g for 1 minute. Then the 
flowthrough is discarded and it is centrifuged at 14000g for 2 minutes. 
The Spin Column is transferred to a new 1.5ml Eppendorf tube, 30µl 
Nuclease-Free Water is added and incubated for 2 minutes. After that it is 
centrifuged at 14000g for 1 minute and the Spin Column is discarded. 
This can also be repeated in order to gain more DNA. The samples are 
stored at -20°C. The yield is between 100 and 300ng/µl. 
 
 
STET boiling plasmid miniprep (according to Stratagene): 
List of materials: 
STET-buffer: 8% Saccharose, 0.5% Triton X-100, 50mM Tris pH8, 
50mM EDTA, filled up to 1L with aqua bidest, autoclaved, stored at 4°C; 
Lysozyme stock: 5mg/ml in STET buffer, stored at -20°C 
STETL buffer: 100µl STET buffer + 10µl lysozyme stock per sample 
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RNase A: 100mg/ml stock (in 10mM Tris-HCl pH 7.5, 15mM NaCl, 
heated to 100°C and cooled to room temperature,  
stored at -20°C 
Isopropanol 
80% EtOH 
Procedures: 
1.5ml cell suspension is filled into in 1.5ml Eppendorf tubes and 
centrifuged at 10000g for 3 minutes. The supernatant is discarded. If 3ml 
cell suspensions are used the previous step has to be repeated but this is 
only recommended for bacteria suspensisons of low density. 110µl 
STETL buffer is added and the pellets are resuspended . The samples are 
heated to 95°C for 1 minute. After that they are centrifuged at 10000g at 
4°C for 10 minutes. The subsequent pellet is removed with a toothpick 
which has been dipped in RNase A solution. 110µl isopropanol is added 
and mixed with the sample. Subsequently, the samples are centrifuged at 
10000 g at 4°C for 15 minutes. The supernatant is discarded. 1ml 80% 
EtOH is added and the pellet is resuspended. Then the samples are 
centrifuged at 10000g at 4°C for 5 minutes. The supernatant is discarded 
completely and the pellet is dried on the heat block at 37°C for 2 minutes. 
The dried pellet is resuspended in 50µl 1xTE and is stored at -20°C. 
 
5.12.4 Restriction digest and agarose gel electrophoresis 
The plasmid is digested by restriction enzymes and the resulting 
fragments are analyzed with 1-1.6% agarose gel. The example in table 
5.12.4.1-3 is calculated for a digest with 2 restriction enzymes. 3 digests 
and 1 control are prepared and incubated at 37°C for 1 hour. The 
substances are mixed and preheated at 37°C before the enzymes are 
added. 
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Table 5.12.4.1 plasmid digest with 2 enzymes 
Amount Substance 
1µl Plasmid sample (app. 200ng) 
1µl 10x Buffer X (Roche or Fermentas) 
7µl Aqua bidest 
0.5µl  Restriction enzyme 1 
0.5µl Restriction enzyme 2 
10µl  Total 
 
Table 5.12.4.2 plasmid digest with 1 enzyme 
Amount Substance 
1µl Plasmid sample (app. 200ng) 
1µl 10x Buffer X (Roche or Fermentas) 
7.5µl Aqua bidest 
0.5µl Restriction enzyme 1 or restriction enzyme 2 
10µl Total 
 
Table 5.12.4.3 control of plasmid digest 
Amount Substance 
1µl Plasmid sample (app. 200ng) 
9µl Aqua bidest 
10µl Total 
 
SeaKem® LE Agarose (Biozym) is used and dissolved in 1x TAE (table 
5.12.4.4 for 50x TAE) is heated and poured to form a 1% agarose gel. The 
agarose gel solidifies in 20 minutes.  
1x TAE is filled into the electrophoresis apparatus and the gel is 
submerged. The 10µl restriction digest are mixed with 2µl 6xDNA 
Loading Dye (Fermentas R0611) and loaded. 2µl Lambda 3 marker (see 
figure 5.12.4.1 and table 5.12.4.5) and 2µl Mass Ruler™ DNA Ladder 
High Range (Fermentas SM0393, see figure 5.12.4.2) are used. The gel is 
run at 90V for 1 hour. The gel is dyed with ethidium solution for 10 
minutes and after that photos are taken in UV light. 
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Table 5.12.4.4 50x TAE (autoclaved) 
Amount Substance 
242g Tris base 
57.1ml Acetic acid 
100ml 0.5M EDTA; ph 8 
Filled up to 1L with aqua bidest 
 
Table 5.12.4.5: Lamba 3 marker 
Amount Substance 
200µl Lambda-DNA (c=0.25µg/µl) 
42µl Buffer B 
4µl HindIII 
4µl EcoRI 
167µl Aqua bidest 
417µl Total 
Digested at 37°C; Then 83µl 6x Loading buffer is added; stored at 4°C; 
Figure 5.12.4.1: Lambda 3 marker Figure 5.12.4.2: Mass Ruler™
DNA Ladder High Range
 
5.12.5 Midiprep 
In this diploma thesis the PureYield™ Plasmid Midiprep System From 
Promega is used for midiprep. 200 ml LB medium is poured into a flask 
and 200µl ampicillin (1:1000 dilution, 100mg/ml) is added. Transformed 
TOP10 bacteria which are stored at -80°C are scraped off with a pipet tip 
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from the ice surface. The pipet tip is thrown into the flask and it is 
incubated at 200rpm at 37°C overnight. Next day the culture is 
centrifuged at 5000g for 10 minutes and the supernatant is discarded. The 
pellet is resuspended in 6ml Cell Resuspension Solution. Subsequently, 
6ml Cell Lysis Solution is added, mixed properly and incubated for 3min. 
After that Neutralization Solution is added and incubated for 3 minutes. 
Then the cell lysate is centrifuged at 15000g for 10 minutes. The Clearing 
Column is placed onto the Binding Column. The cleared lysate is filled 
without pellet debris into the Clearing Column, vacuum is applied and it 
passes through the column combination. Thereby, the plasmid binds on 
the binding membrane of the Binding Column. After that the Clearing 
Column is discarded. 5ml Endotoxin Removal Wash is added and pulled 
through with vacuum. Subsequently, it shall be washed with 20ml Wash 
Solution. Then the Binding Column tip is cleaned and a 1.5 Eppendorf 
tube is placed into the Eluator™ Vacuum Elution Device. The Binding 
Column is inserted into the device. 600µl Nuclease-Free Water is added 
and vacuum is applied in order to fill the 1.5 Eppendorf tube. This step 
can be repeated with 400µl Nuclease-Free Water. 
5.13 Transfection of HT29 cells 
1x106 HT29 cells are plated on 6-well-plates. Cells are ready for 
transfection when they grow adherent. 2µg or 4µg plasmid is diluted in 
250µl serum free medium (450ml MEM, 2ml Penstrep). 10µl 
TransFectin™ Lipid reagent (Bio-Rad) is diluted in 240µl serum free 
medium. Finally, the plasmid mix and TransFectin mastermix are 
combined and incubated at room temperature for 20 minutes. 
Subsequently, the resulting solution is added to the cells in fresh HT29 
cultivation medium (see material and methods 5.1.2.1). After 6 hours the 
medium is changed to HT29 cultivation medium. The expression can be 
detected within the next 3 days. 
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5.14 GFP-FACS analysis 
For 6-well-plates: The HT29 cells are detached with 100µl Trypsin. After 
that 3ml HT29 cultivation medium (see material and methods 5.1.2.1) are 
added and transferred into a 15ml falcon tube which is centrifuged at 
1100rpm for 5 minutes. The supernatant is removed; the pellet is diluted 
in 0.5ml 1xPBS and transferred into FACS tubes. After that the samples 
are analyzed with the FACS machine. 
 
5.15 TOPO® Cloning 
5.15.1 Restriction digest with large amount of DNA 
Table 5.15.1.1 Restriction digest with large amount of DNA 
Amount Substance 
5µg Plasmid sample (in our samples 25 or 35µl) 
5µl 10x Buffer X (Roche or Fermentas) 
14µl or 4µl Aqua bidest (example for our samples) 
0.5µl  Restriction enzyme 1 
0.5µl Restriction enzyme 2 
50µl  Total 
 
Subsquently, the restriction digest with large amount of DNA is tested 
with agarose Gel. The sample is prepared: 2µl of the digest is mixed with 
8µl aqua bidest and 6xDNA Loading Dye (Fermentas R0611). The 
remaining digest is stored at -20°C. 
 
5.15.2 Phosphatase treatment 
Without gel extraction: 
Calf intestinal alkaline phosphatase (CIAP, Fermentas) is used for the 
phosphatase treatment of 5´overhangs. CIAP stock has 1u/µl. CIAP is 
diluted with CIAP 1x Reaction Buffer (Fermentas) to a final concentration 
of 0.01u/µl. Each picomole DNA ends needs 0.01u CIAP. The 
phosphatase treatment master mix of our experiments is in table 5.15.2.1. 
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Table 5.15.2.1 Phosphatase treatment master mix 
Amount Substance 
90µl Nuclease free water 
10µl 10x CIAP Buffer 
1µl CIAP stock 
101µl  Total 
 
5µl phosphatase treatment master mix is combined with 40µl sample 
DNA and 5µl 10x Reaction Buffer and then incubated at 37°C for 30 
minutes. Subsequently, 5µl phosphatase treatment master mix is added 
and incubated again at 37°C for 30 minutes. After that the enzyme is 
inactivated by heat at 85°C for 15 minutes. 
 
With gel extraction: 
CIAP stock (1u/µl, Fermentas) is diluted in this manner that 1µl-2µl CIAP 
dilution is used for the phophatase reaction mix (see table 5.15.2.2). 
Thereby, 2x0.02u CIAP is used per picomole DNA ends. They are 
incubated at 37°C for 15 minutes. Subsequently, the samples are 
incubated at 56°C for 15 minutes. 1µl-2µl of CIAP dilution is added and 
then the samples are incubated at 37°C for 15 minutes. After that they are 
incubated at 56°C for 15 minutes. Finally, the samples are heat-shocked at 
85°C for 15 minutes and then stored at -20°C. 
Table 5.15.2.2 Phosphatase reaction mix 
Amount Substance 
8µl Sample DNA 
1µl 10x Reaction Buffer 
1µl-2µl CIAP dilution 
10-11µl  Total 
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5.15.3 Re-ligation check (sticky-end ligation) 
For ligation, T4 Ligase (5u/µl, Fermentas) was used. A re-ligation check 
master mix is made (see table 5.15.3.1). 
 
Table 5.15.3.1 Re-ligation check master mix ( for 6 samples) 
Amount Substance 
52.6µl Nuclease free water 
6µl 10x T4 DNA Ligase Buffer 
1.4µl T4 DNA Ligase (1u per sample) 
60µl  Total 
 
9µl re-ligation check master mix is added to 1µl sample DNA (approx. 
100ng) and is incubated at room temperature (22°C) for 10 minutes. 
Samples treated with phosphatase and samples without phosphatise 
treatment are ligated in parallel for comparison. Subsequently, the enzyme 
is inactivated by heat at 70°C for 5 minutes. The re-ligation check samples 
are transformed into TOP10 bacteria and analyzed according to 5.12. The 
phosphatase untreated samples expected to cause colonies but 
phosphatase treated samples shall not be able to re-ligate. 
5.15.4 Recessed 3´end filling with TaqPol and dATPs (blunt ends 
production) 
The ends of the constructs which are treated successfully with 
phosphatase (see 5.15.2) are converted into blunt ends. The blunt ends 
mix is prepared on ice (see table 5.15.4.1). Subsequently, the mix is 
incubated at 72°C for 15 minutes. 
Table 5.15.4.1 Blunt ends mix 
Amount Substance 
5µl Phosphatase treated sample 
0.7µl 10x PCR Reaction Buffer (Roche) 
0.5µl 100mM dATP Solution (Invitrogen)  
1µl (0.5u) Taq DNA Polymerase (Roche) 
7.2µl  Total 
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5.15.5 pENTR/D-TOPO® reaction 
pENTR Directional TOPO® Cloning Kit and pENTR/D-TOPO® are used 
for TOPO® cloning. See the pENTR/D-TOPO® reaction mix in table 
5.15.5.1 and is incubated at room temperature for 30 minutes. After that 
the samples are put on ice and are used for transformation and subsequent 
analysis according to 5.12. The pENTR/D-TOPO® vector has a 
kanamycin resistance. The optimal molar insert: vector ratio is 5:1. 
Table 5.15.5.1 pENTR/D-TOPO® reaction mix 
Amount Substance 
2µl Phosphatase treated and blunt ends processed sample 
0.5µl SALT solution 
0.5µl pENTR/D-TOPO® 
3µl Total 
 
5.15.6 Gel excision and Gel extraction (Gel elution) 
Gel extraction is performed before the procedures of 5.15.2. The 
restriction digest of 5.15.1 + 6xDNA Loading Dye (Fermentas R0611) is 
loaded on a 1% agarose gel with large slots. The gel is run at 80V for 2 
hours. After that the bands of interest are cut out of the gel with a scalpel 
under UV light and transferred into new Eppendorf tubes. The QIAEX® 
II gel extraction kit (QIAGEN) is used for gel extraction. 3 volumes of 
buffer QX1 is added to 1 volume of the gel slice (1mg gel = 1µl volume). 
10µl resuspended QIAEX II (≤ 2µg DNA) is added and the samples are 
incubated at 50°C for 10 minutes. During that time the samples are 
vortexed every 2 minutes. The samples are supposed to stay yellow. After 
that the samples are centrifuged at 10000g for 30 seconds and the 
supernatant is discarded. 500µl QX1 is added and the pellet is 
resuspended by vortexing. The samples are centrifuged at 10000g for 30 
seconds and the supernatant is removed. 500µl buffer PE is added and the 
pellet is resuspended by vortexing. The samples are centrifuged at 10000g 
for 30 seconds and all supernatant is removed again. The pellet is air-dried 
for 15 minutes till it becomes white. The DNA is eluted by adding 20µl 
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H2O and the pellet is resuspended by vortexing. The samples are 
incubated at room temperature for 5 minutes (DNA ≤ 4kb) . Subsequently, 
the samples are centrifuged at 10000g for 30 seconds. The pellet is 
resuspended again by vortexing and is incubated 5 minutes. After that the 
samples are centrifuged at 10000g for 30 seconds again. The supernatant 
is transferred into new Eppendorf tubes and is stored at -80°C. 
 
5.16 pENTR-1A cloning: 
5.16.1 BamHI and XhoI digests 
pENTR-1A vector and the concerning pAAV-IRES-hrGFP- Tcf4wt, -ΔN-
Tcf4 or -VP16-ΔN-Tcf4 vectors are digested with BamHI and XhoI in 
separate reactions (see table 5.16.1.1) in the adapted sophisticated attempt. 
The quick method digests both constructs in one sample. 
Table 5.16.1.1 Digest of pENTR-1A or pAAV-IRES-hrGFP-X 
Amount Substance 
Xµl pENTR-1A or pAAV-IRES-hrGFP-X (5µg) 
5µl 10x buffer B  
Xµl Aqua bidest 
3µl  BamHI 
3µl XhoI 
50µl  Total 
 
5.16.2 T4 ligation 
Before ligation dephosphorylation could be done according to 5.15.2 
phosphatase treatment with gel extraction. For ligation, T4 DNA Ligase 
(stock concentration: 5u/µl, Fermentas) was used. The “quick method” of 
pENTR-1A cloning uses the ligation mix in table 5.16.2.1. The 
sophistacted method of of pENTR-1A cloning uses the ligation master 
mix in table 5.16.2.2. 5µl of the ligation master mix is mixed with 5µl 
concerning DNA and nuclease free water. 
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Table 5.16.2.1 quick ligation mix 
Amount Substance 
5µl Digested vector and insert 
1µl 10x T4 DNA Ligase Buffer 
1µl T4 DNA Ligase (1:10 dilution of stock, 0.5u) 
3µl  Nuclease free water 
10µl  Total 
 
Table 5.16.2.2 ligation master mix (for 4 samples) 
Amount Substance 
4µl 10x T4 DNA Ligase Buffer 
0.8µl T4 DNA Ligase stock 
15,2µl  Nuclease free water 
20µl  Total 
 
The successful ligation mix is in table 5.16.2.3. 
Table 5.16.2.3 successful ligation mix 
Amount Substance 
Xµl 
Xµl 
1µl 
Vector 
Insert 
10x T4 DNA Ligase Buffer 
1µl T4 DNA Ligase stock 
Xµl  Nuclease free water 
10µl  Total 
 
The ligation mix is incubated at room temperature for 10-30 minutes 
(longer period of time causes higher transformation efficiency). 
Subsequently, the sample is heat-shocked at 70°C for 5 minutes. 
 
5.16.3 Transformation, platting, inoculation, miniprep and analysis 
Transformation, platting, inoculation, miniprep and analysis are according 
to 5.12. 
131 
5.17 LR reaction 
The LR reaction is done with Gateway® LR Clonase™ II Enzyme Mix 
(Invitrogen). At first entryclone, destination vector and 1xTE buffer are 
mixed in LR reaction mix according to table 5.17.1 or 5.17.2. LR 
Clonase™ II enzyme mix is thawed on ice for about 2 minutes, vortexed 2 
seconds twice and added in the LR reaction mix according to table 5.17.1 
or 5.17.2. Then the samples are mixed twice and microcentrifuged briefly. 
The LR reaction mix is incubated at 25°C for 1 hour. Subsequently, 1µl 
Proteinase K solution is added (full LR reaction mix) in order to terminate 
the reaction and the mix is incubated at 37°C for 10 minutes. After that 
the LR reaction is completed and can be transformed according to 5.12.2. 
Table 5.17.1 full LR reaction mix 
Amount Substance 
Xµl 
1µl 
Xµl 
Entry vector (150ng) 
Destination vector (150ng/µl) 
1xTE buffer (pH8.0) 
2µl LR Clonase™ II enzyme mix 
10µl  Total 
 
Table 5.17.2 half LR reaction mix 
Amount Substance 
Xµl 
1µl 
Xµl 
Entry vector (150ng) 
Destination vector (150ng/µl) 
1xTE buffer (pH8.0) 
1µl LR Clonase™ II enzyme mix 
5µl  Total 
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5.18 Adenoviral production in HEK293 
5.18.1 PacI digest of circular adenoviral constructs 
10µg of circular pAd/CMV/V5-DEST-insert vector is digested with 1.5µl 
PacI (New England Biolabs Inc., #R0547S). The 10x buffer NEBuffer 1 
(New England Biolabs Inc., #B70015) is used. The PacI digest mix is in 
table 5.18.1.1. Additionally, small DNA samples are made which do not 
have restriction enzyme. The digest is incubated at 37°C at 300rpm for 2 
hours or overnight. Subsequently, the digest is heat inactivated at 65°C for 
20 minutes. 10µl of the digest are stored for a gel check. 
 
Table 5.18.1.1 PacI digest mix 
Amount Substance 
Xµl 
40µl 
4µl 
1.5µl 
Circular pAd/CMV/V5-DEST-insert vector (10µg) 
10xNEBuffer1  
100xBSA (New England Biolabs Inc.) 
PacI 
Xµl Nuclease free water 
400µl  Total 
  
5.18.2 Precipitation of linearized adenoviral constructs 
The digest of 5.18.1 is precipitated with sodium acetate and ethanol. The 
centrifuge is pre-cooled. 1/10 Vol (40µl) 3M Sodium acetate solution (pH 
5.2) and 2.5 Vol (1ml) iced cool ethanol are added and the sample is 
vortexed. Then the sample is incubated at -80°C overnight. Subsequently, 
the sample is centrifuged at 14000rpm at 0°C for 15 minutes. After that 
the supernatant is discarded. Then 800µl iced cool 70% ethanol is added 
and the sample is centrifuged at 14000rpm at 0°C for 5 minutes. The 
supernatant is discarded and the pellet is dried. Subsequently, the dried 
pellet is diluted in 20µl 1xTE. 1µl of the sample is filled up to 10µl with 
aqua bidest and this sample is checked together with the control sample of 
5.18.1 by electrophoresis. The amount of DNA is estimated in comparison 
of the λ Marker bands. 
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5.18.3 Transfection of linearized adenoviral constructs 
The transfection takes place in 6-well-plates. 1x105 HEK293 cells are 
plated on wells of 6-well-plates with MEM or DMEM and at 5% or 7.5% 
CO2. DMEM and 7.5%CO2 improve the growth of the HEK293 cells. 
Cells are ready for transfection when they grow adherent and are at least 
50% confluent. 1-2µg plasmid is diluted in 250µl with serum free medium 
(450ml MEM, 2ml Penstrep). 10µl TransFectin™ Lipid reagent (Bio-
Rad) is added to 240µl serum free medium. Plasmid mastermix and 
TransFectin mastermix are poured together and incubated at room 
temperature for 20 minutes. Subsequently, the resulting solution is added 
to the cells in fresh HT29 cultivation medium (see material and methods 
5.1.2.1). After 6 hours the medium is changed by HT29 cultivation 
medium. The cells are cracked according to 5.18.4 if a cytopathic effect 
can be detected. 
5.18.4 Cracking of HEK293 cells 
The attached HEK293 cells are rinsed off the plate with medium and are 
transferred in a falcon tube. It is centrifuged at 1100rpm at room 
temperature for 5 minutes. All supernatant is discarded. The pellet is 
resuspended in PBS and centrifuged as above. After that the supernatant is 
discarded and the pellet is resuspended in new 1ml PBS. Before isolation 
with caesium chloride gradient and viral production in 15cm Pds 10mM 
TRIS-Cl, pH=8 is used.  
Subsequently, the cells are cracked. These steps are repeated 4 times:  
The sample is frozen in liquid N2 and then it is thawed completely in 37°C 
water bath. Subsequently, it is vortexed strongly. 
After cracking the sample is stored at -80°C. 
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5.18.5 Reinfection with cracked HEK293 
Cracked HEK293-virus samples are added to attached, fresh HEK293 
cells. When a cytopathic effect is observed the cells are cracked according 
to 5.18.4. First of all, HEK293 cells are reinfected in 6-well plates, then in 
10cm Pds and at last in 15cm Pds. The fresh cells are splitted one day 
after reinfection. Thereby, 8x106 - 107 HEK293 cells are prepared in 15cm 
plates. The final virus production takes place in 15x15cm Pds. 
5.18.6 Control PCR for pAd/CMV/V5-DEST-insert constructs 
2µl cracked HEK293-virus sample is diluted in 198µl 1xTE (1:100 
dilution) and heat inactivated at 95°C for 15 minutes. pAd/CMV/V5-
DEST-empty and pAd/CMV/V5-DEST-insert are diluted 1:10000 in 
1xTE. Water is used as non-template-control. The control PCR reaction 
mix is listed in table 5.18.6.1. The Taq polymerase synthesizes about 1000 
bps per minute. The program of the control PCR for pAd/CMV/V5-
DEST-insert is in table 5.18.6.2. The PCR starts directly at 95°C (hot 
start). The primer sequences are in table 5.18.6.3. 
 
Table 5.18.6.1: Control PCR reaction mix 
Volume Substance 
12.5µl 2x Go Taq®  Colorless Master Mix (Promega) 
1µl 
1µl 
10.5µl 
T7 primer and V5 primer mix 
Sample DNA (diluted) 
Nuclease free water 
25µl Total 
 
Table 5.18.6.2: Program of the control PCR 
Step number Number of cycles Description 
1 0 1 second at 95°C, hold at 95°C 
PCR samples are inserted then 
2 1 2 minutes at 95°C 
3 35 Denaturation: 30 seconds at 95°C 
Annealing: 1 minute at 55°C 
Synthesis: 4 minutes at 72°C 
4 1 7 minutes at 72°C 
Holding temperature at 5°C 
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Table 5.18.6.3: Primer sequences 
Name Sequence 
T7 primer TAATACGACTCACTATAGGGAGAC 
V5 primer ACCGAGGAGAGGGTTAGGGAT 
 
5.18.7 Isolation of viral particles with caesium chloride gradient 
The final 15x15cm HEK293 Pds which are infected with virus are 
harvested and cracked in 6-8ml 10mM Tris-Cl, ph=8. 
4g caesium chloride is weighed out in a 50ml falcon tube. Subsequently, 
the virus lysate is added and mixed well with caesium chloride. Then the 
sample is filled into an ultracentrifuge tube. A counterweight solution of 
4g caesium chloride and 10mM Tris-Cl, ph=8 is prepared in another 
ultracentrifuge tube and it is tared with the sample tube. The virus sample 
solution is covered with 4 drops petroleum. Subsequently, the 
ultracentrifuge tubes are centrifuged at 32000rpm at 10°C under vacuum 
for 18 hours. The brake is not used in order to let the run terminate 
gradually. In this diploma thesis the Beckman Optima™ LE-80k 
ultracentrifuge is used. 
After that the plastic tubes are pulled out of the ultracentrifuge tubes with 
tweezers and are fixed on a rack in the lamina flow. A beaker containing a 
small amount of proline desinfectant is put under the rack. An adhesive 
strip is stuck on the side of the plastic tube. The virus band is sucked off 
with a 2ml syringe and 18G needle. For this purpose the needle is pierced 
carefully with the needle opening downward through the plastic tube at 
the adhesive strip. The virus solution is filled in falcon tubes, mixed with 
an equal amount of 2x Storage Buffer (10mM Tris, pH=8.0; 100mM 
NaCl; 0.1% BSA; 50% glycerol) and stored at -80°C. 
5.18.8 Virus Titration 
2.5x105 HEK293 cells per well are plated on 24-well-plates. The 
concerning viral band aliquots are diluted 1:10000, 1:100000, 1:1000000 
and 50µl of these dilutions are added in duplicates in the wells. The 
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Adeno-X™ Rapid Titer Kit (Clontech) is used for detection. 1:10000 and 
1:100000 dilution of the LacZ virus of the kit and the 1:1000000 dilution 
of a GFP virus of our lab are used as positive controls. The negative 
control is 50µl 1xPBS. The 24-well-plates are incubated at 37°C for 48 
hours. The medium is discarded and the plates are dried with opened 
cover in the lamina flow for 5 minutes. Subsequently, 1ml ice-cold 
methanol is added and the plates are incubated at -20°C for 10 minutes. 
Methanol is discarded and the wells are washed with 1ml 1xPBS (1% 
BSA). 200µl 1:1000 dilution of the Mouse Anti Hexon Antibody in 
1xPBS/BSA is added per well and the plate is incubated at 37°C for 1 
hour. The antibody solution is removed and filled in the wells of the other 
plate in order to recycle it for one time. Then the first plate is washed with 
1xPBS/BSA and 200µl 1:500 dilution of the Rat anti Mouse-HRP 
conjugate antibody in 1xPBS/BSA is added per well. Again this antibody 
solution is recycled at the second plate. Then the plates are incubated at 
37°C for 1 hour and the wells are washed. After all plates have been 
incubated with the second antibody 200µl DAB dye solution (Dako 
Liquid DAB Substrate Chromogen System; 20µl DAB Chromogen/ml 
Substrate buffer) are added and incubated at room temperature for 10 
minutes.  The dye solution is removed, 1ml 1xPBS is added and the plates 
are analyzed. The plates can be stored including 1xPBS at 4°C. 
The infectious units are calculated: 
[(Infected cells/field)x(fields/well)]/[(volume virus ml)x(dilution factor)]  
At a 10x magnification of the lenses there are 79 fields. 
 
137 
6. Acknowledgements 
I want to give many thanks to Prof. Brigitte Marian who made it possible 
that I could do my practical work and write my diploma thesis in her lab. 
She strongly supported me in the evaluation and discussion of the 
laboratory methods and data. I also want to give thanks to my colleagues 
in the Marian lab who supported me and taught me the needed methods. I 
want to give many thanks to Martin Knöfler (Frauenklinik, Medical 
University Vienna) for providing us the pAAV-IRES-hrGFP-Tcf4 
vectors. Subsequently, I want to give many thanks to Prof. Klaus 
Holzmann and his lab assistant Doris Meiri and PhD student Mag Sandra 
Sampl who helped me strongly to clone the different Tcf4 constructs into 
an adenoviral vector. I also want to give thanks to lab assistant 
Heidemarie Huber of Wolfgang Mikulits Lab who helped me with the 
used ligase and ligase buffer. 
138 
139 
7. References 
Internet sites and text books: 
 
National Cancer Institute – Cancer definition: 
http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer October 
7 in 2011 1pm 
Globocan for all cancers 2008: 
http://globocan.iarc.fr/factsheets/cancers/all.asp October 7 in 2011 1pm 
Clobocan Fast Stasts world 2008: 
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 
October 7 in 2011 3pm 
Globocan Fast Stats Austria 2008: 
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=40 October 
7 in 2011 3 pm 
Globocan colorectal cancer 2008: 
http://globocan.iarc.fr/factsheets/cancers/colorectal.asp October 7 in 2011 
4pm 
Statistik Austria 2011: 
http://www.statistik.at/web_de/statistiken/gesundheit/krebserkrankungen/d
ickdarm_enddarm/index.html October 7 in 2011 4pm 
Alberts B, Johnson A, Lewis J, Raff Martin, Roberts K and Walter P. 
2008. Molecular Biology of The Cell. Fifth Edition. New York: Garland 
Science. Page 1231-1235 and glossary 
Schulte Hermann 1999: Marquardt H, Schäfer S, McClellan and 
Welsch F. 1999. Toxicology. London: Academic Press. Page 179-182 
140 
WHO 2011: http://www.who.int/mediacentre/factsheets/fs297/en/ 
October 7 in 2011 1pm 
Cancer Research UK: http://cancerhelp.cancerresearchuk.org/about-
cancer/causes-symptoms/causes/what-causes-cancer#genetic October 7 in 
2011 1pm 
Junqueira L, Carneiro J and Kelley R. herausgegeben von Manfred 
Gratzl. 2002. Histologie. 5. Auflage. Berlin Heidelberg: Springer Verlag. 
Page 248, 259-268 
Taschenatlas 2003: Fritsch H, Kühnel W. 2003. Taschenatlas der 
Anatomie Band 2 Innere Organe. 8. korrigierte Auflage. Stuttgart: Georg 
Thieme Verlag. Page 202-203. 
Wikipedia 2009 adapted: 
http://en.wikipedia.org/wiki/File:Tubular_adenoma_2_intermed_mag.jpg 
October 25 in 2011 3pm 
 
 
Scientific publications: 
 
 
Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Setinek U, Czech T, 
Marosi C, Buchroithner J, Pichler J, Silye R et al. . 2007. FGF5 as a New 
Oncogenic Factor in Human Glioblastoma Multiforme: Autocrine and Paracrine 
Activities. Cancer Research submitted. 
Altieri DC. 2008. Survivin, cancer networks and pathway-directed drug 
discovery. Nat Rev Cancer 8(1):61-70. 
Altieri DC. 2010. Survivin and IAP proteins in cell-death mechanisms. Biochem 
J 430(2):199-205. 
Camarero N, Mascaró C, Mayordomo C, Vilardell F, Haro D, and Marrero PF. 
2006. Ketogenic HMGCS2 Is a c-Myc Target Gene Expressed in Differentiated 
Cells of Human Colonic Epithelium and Down-Regulated in Colon Cancer. 
Molecular Cancer Research 4(9):645-653. 
141 
Fearon ER, and Vogelstein B. 1990. A genetic model for colorectal 
tumorigenesis. Cell 61(5):759-767. 
Giles RH, Es JHv, and Clevers H. 2003. Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochim Biophys Acta 1653:1-24. 
Guessous F, Li Y, and Abounader R. 2008. Signaling pathways in 
medulloblastoma. Journal of cellular physiology 217(3):577-583. 
Hanahan D, and Weinberg RA. 2000. The hallmarks of cancer. Cell 100(1):57-
70. 
Holnthoner W, Pillinger M, Gröger M, Wolff K, Ashton AW, Albanese C, 
Neumeister P, Pestell RG, and Petzelbauer P. 2002. Fibroblast Growth Factor-2 
Induces Lef/Tcf-dependent Transcription in Human Endothelial Cells. Journal 
of Biological Chemistry 277(48):45847-45853. 
Kinzler KW, and Vogelstein B. 1996. Lessons from hereditary colorectal cancer. 
Cell 87(2):159-170. 
Koornstra JJ, Rijcken FEM, Oldenhuis CNAM, Zwart N, van der Sluis T, 
Hollema H, deVries EGE, Keller JJ, Offerhaus JA, Giardiello FM et al. . 2005. 
Sulindac Inhibits {beta}-Catenin Expression in Normal-Appearing Colon of 
Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous 
Polyposis Patients 
10.1158/1055-9965.EPI-05-0112. Cancer Epidemiol Biomarkers Prev 
14(7):1608-1612. 
Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 
88(3):323-331. 
Lladser A, Sanhueza C, Kiessling R, and Quest AF. 2011. Is survivin the 
potential Achilles' heel of cancer? Adv Cancer Res 111:1-37. 
Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, 
Thaiparambil J, Coward L, Gorman G, Li Y et al. . 2009. A novel sulindac 
derivative that does not inhibit cyclooxygenases but potently inhibits colon 
tumor cell growth and induces apoptosis with antitumor activity. Cancer 
prevention research (Philadelphia, Pa 2(6):572-580. 
Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. 
Nat Rev Cancer 8(12):915-928. 
Reya T, and Clevers H. 2005. Wnt signalling in stem cells and cancer. Nature 
434(7035):843-850. 
Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P, and Ulrich-
Pur H. 2007. CD44-positive colorectal adenoma cells express the potential stem 
cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 
213(2):152-160. 
142 
Sonvilla G, Allerstorfer S, Stattner S, Karner J, Klimpfinger M, Fischer H, 
Grasl-Kraupp B, Holzmann K, Berger W, Wrba F et al. . 2008. FGF18 in 
colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 
29(1):15-24. 
Tu Z, He G, Li KX, Chen MJ, Chang J, Chen L, Yao Q, Liu DP, Ye H, Shi J et 
al. . 2005. An improved system for competent cell preparation and high 
efficiency plasmid transformation using different Escherichia coli strains. 
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, and Ornitz 
DM. 2006. Receptor Specificity of the Fibroblast Growth Factor Family: THE 
COMPLETE MAMMALIAN FGF FAMILY. J Biol Chem 281(23):15694-
15700. 
 
 
143 
8. Zusammenfassung 
Dickdarmkrebs ist der dritthäufigste Krebs weltweit. Er entwickelt sich in einem 
schrittweisen Prozess dessen erster Schritt häufig eine APC Mutation ist. Die 
Konsequenz dieser Mutation ist die progressive Hochregulation des wnt Signalweges, 
weshalb dieser ein bedeutendes Ziel der Therapie ist. Sulindac ist ein Medikament, 
welches den wnt Signalweg inhibiert und bereits in der Präventionstherapie erfolgreich 
eingesetzt wird. In der humanen Colon Adenoma Zelllinie LT97 wurde eine CD44+ 
Subpopulation identifiziert, welche FGF18 und Survivin hochexprimiert und IGF-
bindendes Protein IGFBP3 herunterreguliert. Es ist noch nicht bekannt, ob diese 
Ereignisse kausal mit dem wnt Signalweg in Beziehung stehen. 
 
In meiner Diplomarbeit erforschte ich den Einfluss von Sulindac auf die RNA und 
Protein Spiegel von Survivin, FGF18 und IGFBP3 in LT97 Zellen und in der 
Dickdarmkrebs Zelllinie HT29. Sulindac verursachte eine Herunterregulierung des 
wnt Zielgenes Survivin auf 28% bzw 61% der Kontrolle in HT29 und LT97 Zellen. 
Das Medikament veränderte den IGFBP3 Spiegel in LT97 Zellen nicht. In HT29 
Zellen konnte ein leichter stimulierender Effekt von Sulindac auf den IGFBP3 Spiegel 
beobachtet werden. 
 
Eine dominant negative Tcf4 Mutante wurde in ein adenovirales Konstrukt kloniert 
um eine spezifische Positivkontrolle für die wnt Blockade herzustellen. Das 
ermöglicht die Überexpression der Mutante in allen humanen Zelllinien. 
HT29 und LT97 Zellen wurden mit dem Virus transduziert wodurch eine 4,7 fache 
bzw 1,7 fache Erhöhung der Expression von Tcf4 in LT97 und HT29 Zellen 
verursacht wurde. Signifikante Effekte auf Survivin, FGF18 und IGFBP3 konnten 
nicht detektiert werden. 
 
Die Sulindac Ergebnisse zeigten dass Survivin aber nicht FGF18 und IGFBP3 in einer 
wnt-abhängigen Weise reguliert werden. Mechanistische Experimente mit dem neu 
produzierten Tcf4 Virus sind notwendig um eine wnt-abhängige Reaktion zu 
demonstrieren. 
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